---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Clinical evidence. Covers Integrated externally controlled survival analysis, VTS301 parts A and B, VTS301 part C, VTS-270-001, Expanded access program, and NIH phase 1-2a trial. 329 evidence topics quoted from 58 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 Integrated Externally Controlled Survival Analysis

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Objective of the FDA integrated survival analysis

> “To assess whether Lembaz reduced the risk of death, the FDA examined the survival of 36 patients treated with Lembaz across three clinical studies and an expanded access program.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-3.1.1.1-2"></a>

###### Objectives of the company-presented survival analysis with broader external controls

> “The primary objective was to compare OS (baseline to death or last known alive) in patients with early and late I-NPC treated with adrabetadex vs external controls receiving usual care”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “Compare survival among individuals with infantile-onset NPC treated with adrabetadex to matched external controls”
> “Evaluate long-term disease progression in adrabetadex-treated individuals”

Source: [Berry-Kravis et al. (2026c)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_ACMG_Oral_Survival-NPCCSS-Biomarkers.pdf)

<a id="topic-3.1.1.1-3"></a>

###### Objective of the target trial emulation framework

> “To apply a target trial emulation framework to identify and address potential sources of bias in an externally controlled survival analysis of adrabetadex in I-NPC.”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.1-4"></a>

###### Objectives proposed in the 2021 data request for external controls

> “To determine 1) if early onset patients with NPC treated with adrabetadex show improved survival and delay in loss of ambulation relative to matched untreated patients and 2) if patient cohorts treated long-term with adrabetadex progress more slowly than natural history controls.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.1-5"></a>

###### Objective of the NIH natural history study used as the external control

> “The purpose of this protocol is to obtain both baseline and rate of progression data on clinical and biochemical markers that may later be used as an outcome measure in a clinical trial.”

Source: [ClinicalTrials.gov NCT00344331](https://clinicaltrials.gov/study/NCT00344331)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### NIH natural history study site

> “Participants undergo the following procedures every 6 months during 4- to 5-day admissions at the NIH Clinical Center.”

Source: [ClinicalTrials.gov NCT00344331](https://clinicaltrials.gov/study/NCT00344331)

<a id="topic-3.1.1.2-2"></a>

###### Data cutoff of the company-presented survival analysis, January 2025

> “OS analysis cutoff was January 10, 2025”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.2-3"></a>

###### International registry and French cohort contributing external controls

> “NPC Registry (AC-056C501) is an international, multi-center, prospective, observational, long-term project for patients diagnosed with NP-C”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.2-4"></a>

###### Database lock of the prior sponsor's studies, December 2021

> “The Mallinckrodt databases were locked in December 2021 but other data sources are not yet available.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.2-5"></a>

###### Data cutoff of the company-presented survival analysis, September 2025, superseded in February 2026

> “Miglustat use was permitted; other recently approved therapies were not prohibited in the EAP, but exposure was minimal before the overall survival analysis cutoff (June 24, 2024).”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Integrated survival analysis as the basis of effectiveness in the label

> “The effectiveness of LEMBAZ to reduce the risk of mortality in adult and pediatric patients, who weigh 7 kg or greater, with NPC with neurological manifestations onset prior to 6 years of age was established based on an integrated survival analysis of data from Trials 1, 2, 3, an expanded access program, and Study 1.”
> “Study 1 is an observational, prospective, natural history study of patients with NPC regardless of age or age of neurological manifestation onset.”
> “Matching was based on disease subtype (early vs. late infantile-onset), age of neurological symptom onset (±3 months), and baseline miglustat use (yes vs. no) using a many-to-one matching algorithm.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.3-2"></a>

###### FDA determination that the externally controlled comparison was the adequate and well-controlled study

> “The efficacy of LEMBAZ was based on an overall survival analysis in people with I-NPC treated with LEMBAZ across three clinical studies and an Expanded Access Program, compared with matched external controls.”
> “The FDA determined that this comparison served as the adequate and well-controlled study supporting approval.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-3.1.1.3-3"></a>

###### Externally controlled analysis submitted as a single adequate and well-controlled study

> “The NDA for adrabetadex is supported by data demonstrating a clinically meaningful survival benefit in infantile-onset patients.”
> “This evidence is from an externally controlled analysis intended to serve as a single adequate and well-controlled study.”

Source: [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/)

<a id="topic-3.1.1.3-4"></a>

###### Design rationale stated in the 2021 data request

> “In NPC, placebo/sham-controlled trials are highly challenging due to variability of the disease (1,13), slow progression over years, and limited numbers of patients.”
> “The phase 2b/3 trial of adrabetadex in NPC was subject to all these issues and the control group failed to progress at a rate that would allow a definitive determination of drug effect for adrabetadex (7).”
> “Each patient with disease onset under age 5 years who has been treated with adrabetadex will be matched to as many historical controls as possible from this database and other sources, based on developmental milestones and clinical features and will be compared with respect to age of loss of ambulation and death, as well as other secondary outcomes to be determined based on data available.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.3-5"></a>

###### Company-presented survival analysis with broader external controls: data sources

> “Participants were pooled from the phase 2b/3 trial with open-label extension (VTS301: Parts A/B [NCT02534844] and Part C [NCT04958642, which included participants from Parts A/B and the phase 1/2a study, NCT01747135]) and from Expanded Access Program (EAPs; RUSH IND 119856, VTS-270-001, and Canadian Special Access Program)”
> “This study was sponsored by Mandos, a subsidiary of Beren Therapeutics P.B.C.”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

> “OS was compared with matched external controls from 4 major disease databases or publications.”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “The survival analysis compared adrabetadex-treated individuals (n=72) with infantile neurological onset NPC who participated in a Phase 2b/3 trial and open-label extension period and/or in an Expanded Access Program (EAP) to 119 matched external controls from the NIH Natural History study and three other major disease databases or publications.”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

<a id="topic-3.1.1.3-6"></a>

###### Company-presented survival analysis with broader external controls: target trial emulation

> “Evaluation of therapeutic efficacy in rare diseases may require external controls when data from randomized controlled trials are not available.”
> “Analysis included matched adrabetadex-treated participants from an expanded access program, Phase 1/2a, and Phase 2b/3 studies (n=72) and unique external control participants from prospectively and retrospectively collected natural history cohorts (n=119).”
> “Matching factors included disease subtype, age at neurological onset, age at index, and miglustat use at index.”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.3-7"></a>

###### Company-presented disease progression analysis in treated participants

> “Matching Algorithm Addresses the Most Important Prognostic Factors”
> “Disease progression was assessed in 79 infantile-onset individuals from clinical trials and EAP”

Source: [Berry-Kravis et al. (2026c)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_ACMG_Oral_Survival-NPCCSS-Biomarkers.pdf)

> “The annual rate of clinical disease progression assessed by R4DNPCCSS during adrabetadex treatment was compared with pre-treatment periods.”
> “A longitudinal mixed effects model estimated mean annual rates of change pre- and post-adrabetadex treatment, with R4DNPCCSS scores imputed as 0 at birth to anchor trajectories”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.3-8"></a>

###### Company-presented survival analysis matching, September 2025, superseded in February 2026

> “External controls were matched to adrabetadex-treated participants using a many-to-one algorithm based on baseline age, age at neurological symptom onset, and miglustat use, with weighting to allow reuse of controls.”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Neurological onset before 6 years of age in the label analysis

> “The integrated survival analysis using these data sources included only patients with neurological manifestations onset prior to 6 years old”
> “The matching also required the matched untreated patient from Study 1 to be alive at the age that the treated patient started LEMBAZ treatment (referred to as the index age for a matched stratum).”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “All patients had neurological manifestations of NPC that occurred prior to age 6.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-3.1.1.4-2"></a>

###### NIH natural history study enrollment

> “Patients of any age with NPC may be eligible for this study.”
> “All patients with a diagnosis of NPC, based on clinical presentation, biochemical, or molecular.”

Source: [ClinicalTrials.gov NCT00344331](https://clinicaltrials.gov/study/NCT00344331)

<a id="topic-3.1.1.4-3"></a>

###### Company-presented survival analysis with broader external controls: eligibility for matching

> “Match-eligible adrabetadex-treated participants had early or late infantile-onset NPC and received ≥1 dose of adrabetadex”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

> “Addressed by setting each control's index age to the matched treated participant's age at adrabetadex initiation, with controls required to be alive and already enrolled in their prospective study at that age”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.4-4"></a>

###### Inclusion and exclusion criteria proposed in the 2021 data request

> “Aim 1 inclusion criteria will be children with NPC treated with adrabetadex prior to age 5 years due to neurological symptom onset under age 5 years and untreated matched controls from all sources.”
> “Patients will be excluded from both Aims if they have medical complications or additional diagnoses that would impact the course of NPC.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Treatment exposure and dosage in the label analysis

> “LEMBAZ-treated patients were exposed to LEMBAZ for a median duration of 3.6 years (range: 1.4 months to 8.7 years).”
> “The median final LEMBAZ dosage among the treated patients was 750 mg (range: 300 to 1,050 mg) (the maximum recommended dosage is 900 mg every two weeks).”
> “All studies allowed the concomitant use of miglustat.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.5-2"></a>

###### Company-presented survival analysis with broader external controls: dosing across source studies

> “Adrabetadex was administered intrathecally via lumbar puncture at doses of 50–1200 mg every 4 weeks (Q4W) in phase 1/2a and 900–1800 mg every 2 weeks (Q2W) in VTS301 Part A; 900 mg Q2W was selected as the recommended regimen for VTS301 Parts B and C.”
> “Dose reduction was allowed to manage tolerability.”
> “In the EAPs, participants started at 200 or 400 mg (depending on age) Q2W with titration up to 1200 mg (initially) or 900 mg (later revision)”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.5-3"></a>

###### Company-presented survival analysis with broader external controls: concomitant NPC therapies

> “Miglustat use was permitted; other recently approved therapies were not prohibited in the EAP, but exposure was minimal before the OS analysis cutoff (January 10, 2025)”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.5-4"></a>

###### Treatment definition proposed in the 2021 data request

> “For both Aim 1 and Aim 2 the main predictor/independent variable will be treatment with intrathecal adrabetadex continuously for at least one year.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Overall Survival as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Overall survival definition in the label analysis

> “The survival time was calculated as the time between the index age and the age of last follow-up or death.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.6.1-2"></a>

###### Survival as an outcome in very young children with the fastest progression

> “The only way to truly understand the drug effect in this situation is to look at long-term data and compare treated cohorts with available natural history cohorts, look at within patient pre- and post-treatment rates of decline, and use case-control designs to study very young children who were not a part of the phase 2b/3 trial and who have the fastest rate of progression, thus allowing for the shortest treatment time to pass before outcomes like survival can be assessed.”
> “The overall survival OS is defined as the time from the study entry or randomization to death from any cause.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.6.1-3"></a>

###### Age of neurological onset as the predictor of survival

> “NPC is clinically heterogeneous, with age of neurological symptom onset being the most reliable clinical predictor of disease severity and survival.”
> “Earlier onset is associated with more rapid progression and poorer prognosis, with death often occurring by 5 years of age in early infantile-onset and between 7 and 12 years in late infantile onset.”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="topic-3.1.1.6.1-4"></a>

###### Usual care as the comparator

> “Usual care for NPC has historically involved management of symptoms, with no cure and limited impact on survival.”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.6.1-5"></a>

###### Secondary measure in the company-presented analysis: rescored 4-domain NPC Clinical Severity Scale

> “Disease progression can be assessed using a short-form NPC Clinical Severity Scale (Rescored 4-Domain NPC Clinical Severity Scale [R4DNPCCSS]), which evaluates ambulation, speech, fine-motor function, and swallowing”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

> “Neurological disease progression was assessed pre- and post-adrabetadex-treatment using the 4-Domain Composite NPC Clinical Severity Scale (4DNPCCSS) of ambulation, speech, fine-motor function and swallowing.”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Treated and external control participants in the label analysis

> “A total of 44 control patients with NPC whose neurological manifestations started prior to 6 years of age from Study 1 were eligible for matching to LEMBAZ-treated patients in the integrated survival analysis.”
> “Thirty-six (36) LEMBAZ-treated patients with NPC with neurological manifestations that started at less than 6 years of age from Trials 1, 2, 3, and the expanded access program were matched to external control patients with NPC from Study 1.”
> “The analysis included a total of 26 patients in the external control group from Study 1.”
> “The weighted number of control patients was 36.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.7.1-2"></a>

###### Company-presented survival analysis with broader external controls: 72 treated and 119 matched controls

> “Of 80 total participants treated with adrabetadex eligible for matching, 72 (32 early infantile; 40 late infantile) were successfully matched, with a median treatment duration of 3.8 years (range 0.1–11.1 years).”
> “Of the pooled 255 I-NPC external controls eligible for matching, 119 (57 early infantile; 62 late infantile) were successfully matched”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Sample size in the 2021 data request

> “All planned statistical analyses are exploratory.”
> “No sample size will be calculated, and no minimum sample size was determined a priori.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.7.1-4"></a>

###### Company-presented survival analysis with 66 treated and 110 matched controls, September 2025, superseded in February 2026

> “Of 78 total adrabetadex-treated participants eligible for matching, 66 (32 early; 34 late) were successfully matched, with a median treatment duration of 3.0 years (range 0.2–9.8).”
> “Of the pooled 246 infantile-onset external controls eligible for matching, 110 (53 early; 57 late) were successfully matched.”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Index age, weighting, and statistical models in the label analysis

> “The index age was defined as age at initiation of LEMBAZ treatment for a LEMBAZ-treated patient and its matched control patients.”
> “Control patient data were weighted by the inverse of the total number of matched controls of the LEMBAZ-treated patient.”
> “Estimated from weighted Kaplan-Meier method up to the maximum follow-up time (110 months) in the LEMBAZ-treated group.”
> “Hazard ratio (95% CI) was generated from a weighted Cox regression model including treatment (LEMBAZ-treated vs. matched controls) as fixed effect, and baseline miglustat as a covariate.”
> “The number at risk for the external control group from Study 1 is the rounded integer value of the total sum of the weights for patients at risk.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Company-presented survival analysis with broader external controls: statistical models and censoring

> “Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using a weight-adjusted Cox regression model including treatment (adrabetadex-treated vs matched controls) as fixed effect, and history of miglustat as a covariate”
> “Log-rank P-values were calculated using a weight-adjusted Kaplan-Meier (KM) analysis. Subgroup OS analyses included baseline miglustat use and participants with early and late I-NPC”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “those lost to follow-up or still alive at the last available follow-up were censored”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Company-presented survival analysis with broader external controls: matching with replacement and robust variance

> “For the primary overall survival analysis, external controls were selected based on fitness-for-purpose evaluation and analysed using variable-ratio many-to-one matching with replacement, robust (sandwich) variance with clustering on unique control identifiers, and a frequency-based weight equal to the inverse of the number of controls matched to each treated participant.”
> “The treatment effect was estimated from a weight-adjusted Cox proportional hazards regression model with fixed effects for treatment and baseline miglustat history.”
> “Prespecified subgroup and sensitivity analyses evaluated the robustness of the treatment-effect estimate to alternative assumptions regarding baseline prognostic factors, external-control data source, matching methodology, intercurrent events, outcome ascertainment, censoring, and calendar time.”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.7.2-4"></a>

###### Company-presented survival analysis with broader external controls: prespecified subgroup analyses

| Subgroup analysis | Definition |
| --- | --- |
| Baseline miglustat use | “Participants with and without baseline miglustat use” |
| Source of external control data | “NIH, YODA, and French cohorts considered separately” |
| Age of neurological onset | “Early and late I-NPC subgroups considered separately” |
| Standard-of-care therapy over time | “Participants born before 2010 and born in 2010 or later” |

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.7.2-5"></a>

###### Company-presented survival analysis with broader external controls: sensitivity analyses

| Sensitivity analysis | Definition |
| --- | --- |
| Baseline severity score | “Incorporation of baseline score into the matching algorithm instead of age at neurological onset” |
| Baseline severity by data source | “Source-specific baseline severity measures used in matching (YODA and Freihuber, separately)” |
| Genotype | “Incorporation of genotype category or genetic severity score instead of age at neurological onset” |
| Baseline miglustat use assumed absent | “All Vanier participants assumed to have no miglustat use at baseline” |
| One-to-one matching | “One-to-one matching in place of variable-ratio many-to-one matching” |
| Many-to-one matching without re-use | “Each external control participant used only once, rather than re-used across matched sets” |
| Percentile-based selection of controls | “Selection of controls using the 50th and 100th percentile methods” |
| Other NPC therapy | “Censoring participants at initiation of other NPC therapy” |
| Respiratory therapy | “Censoring at first use of respiratory therapy” |
| Concomitant intravenous adrabetadex | “Participants receiving concomitant IV adrabetadex excluded” |
| Censoring of external control follow-up | “Based on matched treated participants’ follow-up with one-to-one matching” |
| Tipping-point analysis | “Impute censored adrabetadex-treated participants as deaths” |
| One year after the last dose | “Censoring at 1 year after the last dose for participants treated with adrabetadex” |

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.7.2-6"></a>

###### Survival model proposed in the 2021 data request

> “The Primary survival analyses will be performed using an extended Cox model, which will include treatment (adrabetadex-treated vs untreated), category of age at onset of neurological manifestations and country (each country in the NPC Registry and the national cohorts) as covariates.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Source studies of the treated participants and follow-up in the label analysis

> “Of the 36 LEMBAZ-treated patients, 11, 2, 2, and 21 patients originally started LEMBAZ treatment in Trials 1, 2, 3, and the expanded access program, respectively.”
> “Median survival follow-up time from the index age was 5.6 years (range: 1.6 months to 9.2 years) in the LEMBAZ-treated group and 4.2 years (range: 2.5 months to 13.8 years) in the external control group.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.8.1-2"></a>

###### Company-presented survival analysis with broader external controls: movement of participants between source studies

> “Two Study VTS301 Part C participants received open-label adrabetadex in Study VTS-270-302 (a 2-participant study in Costa Rica): 1 continued into the EAP.”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “One Phase 1/2a patient was not in the VTS301 Part C”

Source: [Berry-Kravis et al. (2026c)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_ACMG_Oral_Survival-NPCCSS-Biomarkers.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline characteristics of treated and matched external control participants in the label analysis

> “In both the LEMBAZ-treated group and the external control group, the mean index age was 5.7 years (range: 1 to 19 years).”
> “In both groups, most patients were White (94%); 58% of the LEMBAZ-treated patients were male and 33% of the external control patients were male; 67% of the patients had early infantile-onset NPC in both groups; 50% of the patients were concomitantly treated with miglustat at baseline in both groups.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Company-presented survival analysis with broader external controls: baseline characteristics of 72 treated and 119 matched controls

> “Baseline demographic and clinical characteristics were generally comparable between the 2 groups (Table 1)”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

| Characteristic | Adrabetadex (N=72) | External control (N=119) |
| --- | --- | --- |
| Age at onset under 2 years, n/N (%) | “32/72 (44)” | “57/119 (48)” |
| Age at onset 2 to under 6 years, n/N (%) | “40/72 (56)” | “62/119 (52)” |
| Median age at neurological onset, months (Q1, Q3) | “25 (0, 68)” | “24 (0, 68)” |
| Overall miglustat use, n/N (%) | “52/72 (72)” | “72/119 (61)” |
| Gastrostomy tube, n/N (%) | “11/50 (22)” | “6/26 (23)” |
| Respiratory therapy, n/N (%) | “9/50 (18)” | “2/26 (8)” |
| Race White, n/N (%) | “65/72 (90)” | “22/26 (85)” |
| Race other, n/N (%) | “7/72 (10)” | “4/26 (15)” |
| Region Europe, n/N (%) | “11/72 (15)” | “90/119 (76)” |
| Region North America, n/N (%) | “61/72 (85)” | “27/119 (23)” |
| Region South America, n/N (%) | “0 (0)” | “2/119 (2)” |

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Overall survival in the label integrated survival analysis

> “LEMBAZ-treated patients had longer overall survival compared to the matched external control group, with a 55% reduction in the risk of death (Table 8 and Figure 1).”
> “Longer overall survival was observed independent of baseline miglustat use.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

| Outcome | LEMBAZ (N=36) | External control (N=36) |
| --- | --- | --- |
| Number of deaths (%) | “12 (33.3%)” | “24 (66.9%)” |
| Median survival time in months | “102” | “59” |
| Hazard ratio for risk of death (95% CI) | “0.45 (0.21, 0.95)” | Reference |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### Overall survival as stated by the FDA

> “Patients treated with Lembaz had longer overall survival compared to the matched external control group, with a 55% reduction in the risk of death.”
> “The median survival time was 8.5 years for the treated group compared with 4.9 years in the control group.”
> “This survival benefit was observed regardless of whether patients were also taking miglustat, a therapy used off-label in NPC.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

> “The analysis showed a 55 percent reduction in the risk of mortality.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-3.1.1.8.3-3"></a>

###### Company-presented survival analysis with broader external controls: overall survival in 72 treated and 119 matched controls

> “Participants treated with adrabetadex had a significantly reduced risk of death compared with external control individuals (Figure 2)”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

| Population and comparator source | Deaths, adrabetadex (%) | Deaths, external control (%) | HR (95% CI) | P-value |
| --- | --- | --- | --- | --- |
| Overall infantile | “17 (23.6%)” | “44 (61.2%)” | “0.289 (0.141, 0.593)” | “< 0.0001” |
| Early infantile | “9 (28.1%)” | “24 (76.1%)” | “0.148 (0.064, 0.343)” | “< 0.0001” |
| Late infantile | “8 (20.0%)” | “20 (49.2%)” | “0.344 (0.146, 0.812)” | “0.0457” |
| With miglustat | “8 (22.9%)” | “13 (37.9%)” | “0.361 (0.173, 0.752)” | “0.0205” |
| Without miglustat | “7 (33.3%)” | “19 (91.2%)” | “0.139 (0.049, 0.398)” | “< 0.0001” |
| French comparator | “9 (16.4%)” | “44 (80.7%)” | “0.113 (0.042, 0.301)” | “< 0.0001” |
| NIH comparator | “12 (33.3%)” | “30 (84.2%)” | “0.449 (0.214, 0.946)” | “0.0322” |
| YODA comparator | “8 (21.6%)” | “6 (16.4%)” | “0.381 (0.128, 1.137)” | “0.1426” |

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.8.3-4"></a>

###### Company-presented survival analysis with broader external controls: hazard ratio and five-year survival as announced

> “a 71% reduction in the risk of mortality in adrabetadex-treated patients compared with matched external controls (HR 0.289; 95% CI, 0.141-0.593; P < 0.0001)”

Source: [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/)

> “In the previously reported analysis, a comparison of survival in individuals with infantile-onset NPC treated with adrabetadex to matched external controls showed a 71% reduction in the risk of mortality (p<0.0001).”
> “The 5-year survival rate was 84% for those treated with adrabetadex versus 42% for external controls.”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

<a id="topic-3.1.1.8.3-5"></a>

###### Company-presented survival analysis with broader external controls: consistency across sensitivity analyses

> “Hazard ratio (HR) estimates remained consistent with the primary analysis and supportive of a clinically meaningful survival benefit in I-NPC (HR:0.289, 95% CI:0.141-0.593, p<0.0001).”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.8.3-6"></a>

###### Company-presented disease progression analysis: annual rate of change on the rescored 4-domain NPC Clinical Severity Scale

> “79 treated participants contributed R4DNPCCSS scores.”
> “Adrabetadex treatment significantly reduced the annual rate of disease progression from 1.34 units/year before treatment to 0.76 units per year after treatment (difference 0.58 units/year; 95% CI, –0.98 to –0.18; P=0.0055; Table 2), reflecting a 43% reduction in the annual rate of progression”
> “The mean estimated difference between treated and untreated trajectories of R4DNPCCSS scores after 3 years of adrabetadex treatment was −1.7 (95% CI, −2.94 to −0.53), illustrating a meaningful decrease in R4DNPCCSS scores in participants treated with adrabetadex”

Source: [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)

> “A significantly reduced annual rate of disease progression of 43% (p=0.0055) over 52 weeks compared with pre-treatment rates of disease progression.”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

<a id="topic-3.1.1.8.3-7"></a>

###### Company-presented survival analysis with 66 treated and 110 matched controls, September 2025, superseded in February 2026

> “Adrabetadex was associated with a significantly reduced risk of death (Figure 2; Table 2).”
> “Overall survival showed directional consistency for the adrabetadex-treated group across all external control cohorts”

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

| Population and comparator source | Deaths, treated (%) | Deaths, control (%) | Hazard ratio (95% CI) | P-value |
| --- | --- | --- | --- | --- |
| Overall infantile, pooled comparator | “9 (13.6%)” | “42 (63.3%)” | “0.162 (0.069, 0.380)” | “<0.0001” |
| Early infantile, pooled comparator | “6 (18.8%)” | “23 (72.8%)” | “0.109 (0.035, 0.333)” | “<0.0001” |
| Late infantile, pooled comparator | “3 (8.8%)” | “18 (54.3%)” | “0.148 (0.040, 0.546)” | “0.0036” |
| With miglustat | “2 (7.1%)” | “12 (41.8%)” | “0.097 (0.023, 0.406)” | “0.0005” |
| Without miglustat | “5 (21.7%)” | “18 (79.9%)” | “0.123 (0.036, 0.425)” | “<0.0001” |
| French comparator | “5 (9.8%)” | “42 (82.1%)” | “0.073 (0.023, 0.236)” | “<0.0001” |
| NIH comparator | “5 (15.2%)” | “24 (71.2%)” | “0.176 (0.060, 0.517)” | “<0.0001” |
| YODA comparator | “4 (11.4%)” | “6 (17.9%)” | “0.298 (0.082, 1.086)” | “0.1168” |

Source: [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: limitations of the integrated externally controlled survival analysis

- Design: the comparison is with external controls. A statistical methods poster on the analysis states that externally controlled analyses are susceptible to bias from differences in baseline prognosis, treatment initiation at different ages, calendar time and standards of care, and post-baseline therapies, and that target trial emulation identified four principal threats: prognostic factor confounding, post-baseline treatment confounding, immortal time bias, and temporal bias. Both the label analysis and the company analysis required each matched control to be alive at the treated participant's age at treatment initiation.
- Label analysis: all 26 external control participants came from Study 1 and were weighted to a number of 36 against 36 treated participants. Matching used disease subtype, age of neurological symptom onset (±3 months), and baseline miglustat use; 58% of treated and 33% of control participants were male, median follow-up from the index age was 5.6 and 4.2 years, and index ages ranged from 1 to 19 years. The label states that safety and effectiveness in reducing mortality with neurological onset at 6 years of age or older has not been established.
- Analysis with broader external controls: 72 treated participants were matched with 119 external controls drawn from 4 major disease databases or publications, and the poster states that comparability factors were not available from all sources.
- Variation in the estimate: the hazard ratio differed by comparator source (French 0.113; NIH 0.449, 95% CI 0.214 to 0.946; YODA 0.381, 95% CI 0.128 to 1.137, P = 0.1426) and between data cuts (0.162 with 66 treated participants at the June 24, 2024 cutoff; 0.289 with 72 at the January 10, 2025 cutoff). The label analysis reported 0.45 (0.21, 0.95). The statistical methods poster reported that hazard ratio estimates across its prespecified sensitivity analyses remained consistent with the primary analysis.
- Analysis plan: the YODA Project data request that proposed the external control analysis stated that “All planned statistical analyses are exploratory” and that no minimum sample size was determined a priori.

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf); [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf); [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.1.9-2"></a>

###### Indication limited to neurological onset before 6 years of age

> “the safety and effectiveness of LEMBAZ to reduce mortality in patients with NPC with neurological manifestation onset at 6 years of age or older has not been established”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.1.9-3"></a>

###### Sources of bias in externally controlled survival analyses

> “However, externally controlled analyses are susceptible to bias from differences in baseline prognosis, treatment initiation at different ages, calendar time and standards of care, and post-baseline therapies.”
> “Target trial emulation made the causal design explicit and identified four principal threats to inference in an externally controlled survival analysis: prognostic factor confounding, post-baseline treatment confounding, immortal time bias, and temporal bias.”

Source: [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.1.9-4"></a>

###### Incomplete comparability data across external control sources

> “Comparability factors were not available from all sources.”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 VTS301 Parts A and B

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Primary objectives of Parts A and B

> “The primary study objective in Part A was to select the dose of VTS-270 to be used in Part B and Part C.”
> “The primary study objective in Part B is to evaluate, in a double-blind sham-controlled design, the progression of the neurologic manifestations of NPC1 disease following 52 weeks of treatment for subjects treated with VTS-270 compared to sham control, using the following assessments:”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.1-2"></a>

###### Key secondary objective of Part B

> “The key secondary objective for Part B is to evaluate the progression of the neurologic manifestations of NPC1 disease using the total NPC-SS score, excluding the hearing domain and auditory brainstem response (ABR) modifier results, following 52 weeks of treatment for subjects treated with VTS-270 compared to sham controls and the Caregiver CGIC.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.1-3"></a>

###### Registry statement of purpose

> “This study is to find out how safe and effective VTS-270 is for patients with Niemann-Pick Type C1 (NPC1) disease who have neurologic symptoms (listed under Keywords).”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.1-4"></a>

###### Objective of the post hoc cerebrospinal fluid biomarker analysis

> “Assess treatment effects of adrabetadex in CSF levels of 24(S)-OHC, calbindin D, and FABP3 over 52 weeks.”

Source: [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registry study dates and enrollment

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2015-10” |
| Primary completion (actual) | “2018-03-28” |
| Study completion (actual) | “2018-03-28” |
| Enrollment (actual) | “56” |
| Results first posted | “2023-02-22” |

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.2-2"></a>

###### Study sites by country

> “This study has 29 locations”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

| Country | Facility |
| --- | --- |
| United States | “University of Alabama at Birmingham” |
| United States | “Children's Hospital of Orange County” |
| United States | “University of California San Francisco” |
| United States | “University of Colorado Denver” |
| United States | “Shands Children's Hospital” |
| United States | “Rush University Medical Center” |
| United States | “Eunice Kennedy Shriver National Institute of Child Health and Human Development” |
| United States | “Boston Children's Hospital” |
| United States | “Montefiore Medical Center” |
| United States | “University of North Carolina” |
| United States | “Lehigh Valley Health Network” |
| United States | “The Children's Hospital of Philadelphia” |
| United States | “Dell Children's Medical Center of Central Texas” |
| United States | “Multicare Institute for Research and Innovation” |
| Australia | “The Prince of Wales Hospital” |
| Australia | “Monash Medical Centre” |
| Australia | “Royal Melbourne Hospital” |
| Australia | “Royal Perth Hospital” |
| France | “CHU Paris Est - Hospital d'Enfants Armand-Trousseau” |
| Germany | “Katholisches Klinikim Bochum gGmbH” |
| Germany | “Universitaetsklinikum Mainz” |
| Germany | “Universitaetsklinikum Muenster” |
| New Zealand | “Waikato Hospital” |
| Singapore | “National University Hospital (Singapore) Pte, Ltd” |
| Spain | “Hospital Universitario del Valle Hebron” |
| Turkey | “Hacettepe University Medical Faculty” |
| Turkey | “Gazi University Medical Faculty” |
| United Kingdom | “Great Ormond Street Hospital” |
| United Kingdom | “Birmingham Women's and Children's NHS Trust” |

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.2-3"></a>

###### Planned number of sites and regulatory oversight

| Field | Quoted record |
| --- | --- |
| Number of Sites | “Approximately 24 sites worldwide” |

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “The study was regulated by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and approved by a central IRB as well as the IRB of each study site.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Multicenter, randomized, double-blind, sham-controlled three-part design

> “This is a multicenter, multinational, prospective, randomized, double-blind, sham-controlled, 3-part, efficacy and safety trial of VTS-270 administered by the lumbar intrathecal (IT) route every 2 weeks, with a planned enrollment of approximately 51 subjects (in Parts A and B) with Niemann-Pick type C1 (NPC1) disease.”
> “Part A evaluated 3 different dose levels of VTS-270 versus sham control, administered as 4 lumbar IT injections every 2 weeks, to determine the dose level for Parts B and C.”
> “Part C will be an open-label extension phase of the study.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.3-2"></a>

###### Label description of Trial 1 Parts A and B

> “Trial 1 Part A/B was a 52-week, double-blind, sham-control trial in 56 patients with NPC who received intrathecal LEMBAZ every 2 weeks for 52 weeks or sham treatment [see Clinical Studies (14)].”
> “Part A and Part B (NCT02534844) included a 52-week, randomized, double-blind, and sham-controlled period and enrolled 56 treatment-naïve patients.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.2.3-3"></a>

###### Randomization ratios, dose selection, and rescue option

> “In Part A, 12 subjects were randomly assigned to one of four study arms (1:1:1:1), and received either one of three dose levels of adrabetadex (900 mg, 1200 mg, or 1800 mg per IT via LP) or sham procedure (no lumbar puncture).”
> “Following dose selection in Part A, 44 additional subjects were randomized 2:1 to receive either study drug at the dose level chosen in Part A (900 mg) or sham.”
> “Subjects enrolled in Part B who manifested significant disease progression according to predefined clinical criteria after treatment of 26 weeks or more had the option to escape the blinded trial early and enter Part C.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="topic-3.1.2.3-4"></a>

###### Dose selection committee and stratification of Part B randomization

> “Evaluation of hearing loss across the different doses was included as part of the dose selection process.”
> “The goal of the DSC was to select the highest dose with acceptable safety and tolerability to be administered in Parts B and C of the study.”
> “Although randomization in Part B is stratified by miglustat use and baseline NPC‐SS level to ensure balance across the 2 treatment groups, the statistical analyses will not be stratified”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.3-5"></a>

###### Sham procedure and blinding

> “The sham procedure will consist of 1 to 2 small needle pricks on the lower back at the location where the LP and IT injection is normally made.”
> “The needle(s) will break the skin but no lumbar puncture or needle insertion will occur.”
> “Parents/caregivers will not be present in the room during lumbar IT or sham treatment.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “While it is a double-blind trial, the participant and outcomes assessor will be blinded, as well as the Care Provider and Investigator.”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.3-6"></a>

###### Sponsor rationale for the sham control

> “The sham procedure control (monitored anesthesia care [conscious sedation] or if medically necessary, general anesthesia, and 1 to 2 skin needle pricks) minimizes both undue risk to the NPC1 subjects and the potential for bias.”
> “Subjects enrolled in the VTS301 study were randomly assigned in a 3:1 ratio (in Study Part A) or a 2:1 ratio (in Study Part B) to receive either IT administered VTS-270 or a sham control procedure.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.2.3-7"></a>

###### Duration of participation in Parts A and B

> “Total duration of subject participation in Parts A and/or B will be approximately 58 weeks, to include a screening period of up to 45 days (maximum), and 52 weeks of serial IT injections or sham control procedures given on a 2-week cycle.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Age, age at neurological onset, and diagnosis

> “Male or female subjects, 4 to 21 years of age at time of screening, with onset of neurological symptoms prior to 15 years of age.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “Trial 1 was a trial in patients aged 4 to 21 years old and with onset of neurological manifestations prior to 15 years old, and included Parts A, B, and C:”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Has confirmed diagnosis of NPC1 determined by either:”
> “two NPC1 mutations”
> “positive filipin staining and at least one NPC1 mutation”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.4-2"></a>

###### Disease severity required at entry

> “Has an NPC Clinical Severity Scale Score of 1 through 4, inclusive, in two or more of the following components: ambulation, fine motor skills, or swallowing; and has a score of 0 through 4 on the cognition component”
> “Has a total NPC Clinical Severity Scale Score of 10 or greater”
> “Unable to walk, wheelchair dependent (ambulation NPC score=5)”
> “Has need for a nasogastric tube to overcome swallowing difficulties (swallowing NPC score=5) unless used for supplemental feeding or administering medication”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.4-3"></a>

###### Body weight, prior cyclodextrin, and antipsychotic exclusions

> “Subjects meeting any of the following criteria are to be excluded:”
> “Body weight < 15 kg.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “Has had prior treatment with intravenous 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) for NPC1 disease, unless the subject has undergone a minimum 3-month washout period prior to Study Day 0, or has had any prior intrathecal (IT) administration of HP-β-CD”
> “Is taking antipsychotics for treatment of psychosis; use of antipsychotic medication for treatment of other disorders (e.g., Attention Deficit Hyperactivity Disorder) will not exclude participation in this trial”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.4-4"></a>

###### Washout of supplements and investigational treatments

> “Agree to discontinue all nonprescription supplements such as coenzyme Q10, curcumin, cinnamon, fish oil supplements, high-dose vitamin D (> 500 mIU/day), N-acetylcysteine, acetylleucine, or gingko biloba at least 1 month prior to first dose (Study Day 0).”
> “Agree to discontinue any other investigational treatments for NPC including, for example, vorinostat or arimoclomol at least 3 months prior to first dose (Study Day 0).”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Dosage by part in the label

> “In Part A, the LEMBAZ intrathecal dosage was 900 mg every two weeks, 1,200 mg every two weeks (1.3 times the maximum recommended dosage), and 1,800 mg every two weeks (twice the maximum recommended dosage) and in Part B, the LEMBAZ intrathecal dosage was 900 mg every two weeks.”
> “Six patients received at least one dose above 900 mg [see Overdosage (10)].”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.2.5-2"></a>

###### Dose reduction for drug-related adverse events

> “Subjects who, in the opinion of the investigator, experience a drug-related adverse event (AE) after any blinded IT treatment that is considered clinically relevant and impactful to the subject’s function may have their dose reduced to 600 mg per IT administration for subsequent IT dosing intervals following discussion with the unblinded medical monitor.”
> “If, following dose reduction to 600 mg, a subject continues to experience AEs as described above, the subject’s dose may be further reduced to 400 mg per IT administration for subsequent dosing intervals following discussion with the unblinded medical monitor.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.5-3"></a>

###### Intrathecal administration procedure

> “The LP and/or sham is to be performed under monitored anesthesia care (conscious sedation) with an appropriate oral or IV agent and performed by an unblinded study physician.”
> “VTS-270 will be administered as an IT slow bolus (1 to 2 minutes, depending on the volume administered) LP injection (maximum rate of administration = 4.5 mL/minute).”
> “Prior to the VTS-270 injection, a volume of CSF fluid approximately equal to the VTS-270 dose is to be removed.”
> “All subjects, sham and study drug, are required to lie flat with feet elevated for 30 to 45 minutes following dosing.”
> “For the 3 days following each procedure, subjects in both the sham and active treatment groups are to avoid acoustic overstimulation and minimize exposure to loud noises, e.g., headphones for music or video games.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.5-4"></a>

###### Concomitant miglustat

> “If taking miglustat, must have been on a stable dose for the past 6 to 8 weeks and be willing to remain on a stable dose for the duration of participation in Parts A and B of the study.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.5-5"></a>

###### Sham control intervention in the registry

> “No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using the 4-Item NPC Severity Scale Composite Score as a Co-primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Co-primary endpoints: NPC-SS composite score and clinician CGIC at Week 52

> “Change from baseline in NPC-SS composite score at Week 52 in the group treated with VTS-270 vs. the sham control group.”
> “Blinded Clinician CGIC at Week 52 in the group treated with VTS-270 vs the sham control group.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.6.1-2"></a>

###### Scoring of the 4-item composite and the clinician CGIC

> “Each of the four NPC-SS components (ambulation, cognition, fine motor, and swallowing) are rated on a scale from 0 (better) to 5 (worse).”
> “The total score was the sum of individual components scores which ranges from 0 (best) to 20 (worst), with higher scores indicating more severe clinical impairment.”
> “The Investigator rates his/her impression of the change in each participant's condition at week 52 on a scale from marked improvement (1) to marked worsening (7).”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.6.1-3"></a>

###### Key secondary endpoints as revised in the statistical analysis plan

> “The list of key secondary endpoints in the protocol has been changed to the following:”
> “Change from baseline to Week 52 in the NPC‐SS total score with the hearing domain and ABR modifiers removed”
> “The following key secondary endpoint described in the protocol has been changed to the first other secondary endpoint:”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.6.1-4"></a>

###### Selection of the 4-item composite score for this trial

> “Vtesse, Inc., now a Mallinckrodt Pharmaceuticals company, selected the four-item composite score as the primary efficacy endpoint in the Phase 2/3 multicenter clinical trial of intrathecal adrabetadex in NPC1”
> “The NPC-SS and particularly the 4- and 5-item scales represent key domains identified by families and clinicians as important to quality of life.”
> “All domains were rated except those involving hearing as hearing information was being monitored seperately in the trial to track this as an adverse event, the hearing rating was not part of the efficacy score as the drug can cause hearing loss, and hearing information might have unblinded the NPC-SS raters to treatment status.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="topic-3.1.2.6.1-5"></a>

###### Inter-rater reliability of central NPC-SS scoring in this trial

> “The objective of the study was to examine the inter-rater reliability of the NPC-SS in a Phase 2/3 clinical trial.”
> “Clinical data recorded at each study site were distributed to two independent blinded central raters to generate a severity score.”
> “The average ICCs for absolute agreement for the 4-item and 5-item scales, respectively, were ICC (3,2) = 0.95 [95% CI = 0.93, 0.97] and 0.96 [95% CI = 0.93, 0.97] for the multiple assessment, and ICC (3,1) = 0.91 [95% CI = 0.87, 0.94] and 0.92 [95% CI = 0.87, 0.94] for the single assessment (Supplemental Data, Table 9).”
> “For the NPC-SS 4-item composite score, the average kappa was 0.36 [95% CI= 0.31, 0.42], the average weighted kappa was 0.76 [95% CI= 0.73, 0.79], and the average percent agreement between raters was 40.9% (95% CI= 35.2, 46.6).”
> “These results support the NPC-SS, including derived 4- and 5-item composite scores, as reliable measures for use in a clinical trial setting.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="topic-3.1.2.6.1-6"></a>

###### Development of the NPC clinical severity scale

> “Thus, we developed a clinical severity scale to characterize and quantify disease progression.”
> “Both patient cohorts showed a linear increase in severity scores over time.”

Source: [Yanjanin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2798912/)

<a id="topic-3.1.2.6.1-7"></a>

###### Content validity and meaningful change of the 5-domain scale

> “Domains identified as most important by clinicians, caregivers, and patients (independent of current age, age of onset, and disease severity) were Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills, indicating content validity of the 5-domain NPCCSS.”
> “Meaningful change using trial data and interviews with NPC experts (n = 5) and patients/caregivers (n = 28) suggested that a 1-category change on a domain is equivalent to 1-point change or greater in the 5-domain NPCCSS total score.”

Source: [Patterson et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7881637/)

<a id="topic-3.1.2.6.1-8"></a>

###### International Delphi consensus on severity scales

> “Consensus was reached (74%) for the 17-domain NPCCSS scale as the first choice in clinical trial settings, but the domains measured in the 5-domain scale should be prioritised as the primary endpoints.”
> “Several scales have been developed and published over the past two decades but, essentially, all are based on a four-domain scale initially developed by Iturriaga et al.”

Source: [Evans et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8600786/)

<a id="topic-3.1.2.6.1-9"></a>

###### Convergent validity of scale domains, including data from this trial

> “Participants were drawn from several studies performed at two sites at which participants with clinically and biochemically confirmed NPC were followed with regular clinical evaluations, including a natural history study for NPC (NCT00344331), a phase 1/2a trial of intrathecal 2-hydroxypropyl-beta-cyclodextrin (adrabetadex, NCT01747135), a phase 2b/3 trial of adrabetadex (NCT02534844), and an expanded access program for treatment of NPC with adrabetadex (IND119856).”
> “The 5DNPCCSS domains were significantly related in the expected directions to their respective direct assessments, supporting their construct validity.”
> “In the years since its publication, researchers and regulators have noted that the wide-ranging composition of the NPC-CSS-17, meant to capture the full range of clinical presentation, might reduce its ability to detect an effect of intervention.”

Source: [Farmer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12353886/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned sample size and its basis

> “The sample size was determined based on the potential number of available subjects for this ultra-rare disorder.”
> “Based on the comparison of the NIH phase 1 subjects and similar subjects in the NIH natural history data set, approximately 51 subjects, 16 on sham and 35 on active treatment, will allow for the detection of clinically relevant difference of the sum of the 4 NPC-SS score domains that make up the composite outcome.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.2.7.1-2"></a>

###### Power calculation assumptions

> “The VTS‐270 group has an average increase in value over 52 weeks ranging from 0 points to 0.2 points.”
> “The sham group has an average increase in value over 52 weeks ranging from 1.6 points to 1.9 points.”
> “Based on these assumptions, an analysis of covariance (ANCOVA) will have 79% power to detect a statistically significant difference between the VTS‐270 and sham groups.”
> “Three additional subjects above the planned sample size were enrolled into the study, such that there were 54 subjects randomized.”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants analyzed for the co-primary endpoints

| Analysis | Sham control | Adrabetadex |
| --- | --- | --- |
| 4-item NPC-SS composite, participants analyzed | “18” | “38” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.7.1-4"></a>

###### Participants analyzed for secondary endpoints

| Outcome measure | Sham control | Adrabetadex |
| --- | --- | --- |
| NPC-SS total score excluding hearing and ABR | “18” | “37” |
| Annualized rate of change (slope) of NPC-SS composite | “14” | “34” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Analysis populations in the protocol

> “The modified intent-to-treat (mITT) population will consist of all randomized subjects who received at least one dose of VTS-270 infusion or sham control.”
> “The primary population for the primary efficacy assessment will be the mITT.”
> “The per-protocol (PP) population will consist of all randomized subjects who had no major protocol deviation that would have had an impact on the primary outcome and who received at least 75% of their scheduled VTS-270 IT administrations.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.7.2-2"></a>

###### Modified intent-to-treat population as defined in the statistical analysis plan

> “The modified intent‐to‐treat (mITT) population will consist of all randomized subjects in Parts A and B who received at least one dose of 900 mg of VTS‐270 infusion or sham control.”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Analysis populations in the registry results

> “mITT population included all randomized participants who received at least one treatment (sham or adrabetadex).”
> “Safety population was defined as all randomized participants who received at least 1 procedure (adrabetadex infusion via LP or sham).”

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.7.2-4"></a>

###### Primary analysis method and handling of missing data

> “To protect against the potential bias that may occur if outcomes for the completers are different from those for the non‐completers (i.e., missing not at random; MNAR), the approach taken will be to impute all missing observations from either treatment arm as if they came from the sham group.”
> “An ANCOVA, with treatment group, study part, and baseline NPC‐SS composite score included in the model, will be performed to test for differences in the change from baseline to Week 52 between VTS‐270 and sham groups in the co‐primary efficacy outcome measure.”
> “Considering the small sample size, this ANCOVA will be performed using a nonparametric approach such that the outcome data will be ranked.”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.7.2-5"></a>

###### Clinician CGIC analysis and hierarchical testing of key secondary endpoints

> “The analysis of the blinded Clinician CGIC at Week 52 will be conducted using the nonparametric Van Elteren method to test for the treatment effect using study part as a blocking variable.”
> “The following key secondary endpoints comparing subjects treated with VTS-270 with the sham controls will be analyzed using a hierarchical testing, serial gatekeeping strategy based on the mITT population.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.7.2-6"></a>

###### Statistical methods of the post hoc biomarker analysis

> “Wilcoxon signed-rank test was used to assess within-group changes in CSF biomarkers from baseline to Week 52 (SAS v9.4).”
> “Nominal statistical significance was defined as P<0.05 without adjustment for multiplicity”

Source: [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Participant flow in the ClinicalTrials.gov record

| Milestone | Part A adrabetadex 900 mg | Part A adrabetadex 1200 mg | Part A adrabetadex 1800 mg | Part A sham | Part B adrabetadex 900 mg | Part B sham |
| --- | --- | --- | --- | --- | --- | --- |
| Started | “3” | “3” | “3” | “3” | “29” | “15” |
| Completed | “3” | “3” | “3” | “3” | “27” | “14” |
| Not completed | “0” | “0” | “0” | “0” | “2” | “1” |
| Withdrawal by subject | “0” | “0” | “0” | “0” | “2” | “1” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.1-2"></a>

###### Discontinuations due to adverse events

> “No participants discontinued the study due to treatment-emergent adverse events (TEAEs) in Part A/B of VTS301.”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline demographics of the intent-to-treat population in the ClinicalTrials.gov record

| Characteristic | Sham control (n = 18) | Adrabetadex (n = 38) | Total (n = 56) |
| --- | --- | --- | --- |
| Age, years, mean (SD) | “11.7(5.10)” | “12.7(5.64)” | “12.4(5.45)” |
| Female | “10” | “16” | “26” |
| Male | “8” | “22” | “30” |
| White | “16” | “31” | “47” |
| Asian | “1” | “4” | “5” |
| Hispanic or Latino | “3” | “3” | “6” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.2-2"></a>

###### Baseline 4-item NPC-SS composite score

| Statistic | Sham control | Adrabetadex |
| --- | --- | --- |
| Baseline mean | “8.1” | “8.8” |
| Baseline standard deviation | “4.27” | “3.12” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.2-3"></a>

###### Baseline weight, miglustat use, seizures, symptom duration, and total severity score

| Characteristic | Adrabetadex (N=38) | Sham control (N=18) |
| --- | --- | --- |
| Weight (kg), mean (SD) | “48.1 (25.27)” | “40.2 (18.98)” |
| Miglustat use, n (%) | “25 (66)” | “9 (50)” |
| Seizures, n (%) | “15 (39)” | “5 (28)” |
| Duration of neurologic symptoms (years), mean (SD) | “7.1 (4.15)” | “5.9 (5.16)” |
| Baseline NPC-CSS total score (minus hearing/ABR), mean (SD) | “17.8 (6.48)” | “16.9 (8.16)” |

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.2.8.2-4"></a>

###### Label demographics of participants receiving up to 900 mg and sham

> “There were 32 patients who received up to 900 mg in the LEMBAZ treatment group and 18 in the sham-control group with a mean age of 12 years old (minimum age 4, maximum age 22).”
> “Patients in Trial 1 were 24 female (48%), 26 male (52%).”
> “Twenty-eight patients (56%) experienced neurological symptom onset at <6 years of age.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.2.8.2-5"></a>

###### Cerebrospinal fluid biomarker analysis subset

> “This biomarker study included 34 participants (Table 1), with a mean age of 12.8 years and mean age at neurological onset of 5.7 years”
> “About two-thirds were also receiving miglustat”

Source: [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Co-primary endpoint: change in 4-item NPC-SS composite score at Week 52

| Statistic | Sham control (n = 18) | Adrabetadex (n = 38) |
| --- | --- | --- |
| Change from baseline at Week 52, mean | “-0.1” | “0.0” |
| Change from baseline at Week 52, standard deviation | “1.55” | “2.45” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.3-2"></a>

###### Co-primary endpoint: clinician CGIC at Week 52

| CGIC category | Sham control (n = 18) | Adrabetadex (n = 38) |
| --- | --- | --- |
| Markedly improved (1) | “0” | “0” |
| Moderately improved (2) | “1” | “5” |
| Minimally improved (3) | “4” | “9” |
| Unchanged (4) | “9” | “16” |
| Minimally worse (5) | “2” | “6” |
| Moderately worse (6) | “2” | “1” |
| Markedly worse (7) | “0” | “1” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.3-3"></a>

###### Sponsor statements of the Parts A and B result

> “The results of the Company’s recently completed registration trial for the product did not show a statistically significant separation from placebo.”
> “Neither the VTS-270 nor the placebo arm showed disease progression as would be expected for a neurodegenerative condition over 52 weeks of observation.”

Source: [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)

> “Analysis of data from Part A/B of this study shows no benefit of adrabetadex on the pre-specified co-primary endpoints.”
> “For those subjects who appear to benefit from treatment, the investigator must review with them the risks associated with intrathecal adrabetadex, including hearing loss, and the data from the randomized, controlled trial that demonstrated no significant differences between patients treated with adrabetadex and sham-treated subjects on any efficacy measures.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.2.8.3-4"></a>

###### Post hoc analysis by miglustat use

> “A post-hoc analysis evaluating the effect of miglustat use showed that subjects receiving miglustat (with or without adrabetadex) show evidence of disease stabilization but subjects receiving adrabetadex without miglustat show disease worsening comparable to sham subjects not on miglustat.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.2.8.3-5"></a>

###### Secondary endpoints reported in the ClinicalTrials.gov results

| Outcome measure | Sham control | Adrabetadex |
| --- | --- | --- |
| NPC-SS total score excluding hearing and ABR, change at Week 52, mean (SD) | “-0.74(2.357)” | “-0.34(4.226)” |
| Responders on NPC-SS total score excluding hearing and ABR at Week 52, participants | “13” | “22” |
| Participants who qualified for the rescue option | “2” | “2” |
| Time to one-point worsening in NPC-SS composite score, median days (95% CI) | “118 (55 to 364)” | “169 (70 to 278)” |
| 9-Hole Peg Test, change at Week 52, seconds, mean (SD) | “-1.49(15.958)” | “-1.79(34.760)” |
| Annualized rate of change (slope) of NPC-SS composite, mean (SD) | “-0.05(1.640)” | “0.08(2.441)” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.3-6"></a>

###### Timed Up and Go test and total NPC-SS including hearing

| Outcome measure | Sham control | Adrabetadex |
| --- | --- | --- |
| Timed Up and Go, change at Week 52, seconds, mean | “0.86” | “2.70” |
| Timed Up and Go, change at Week 52, seconds, SD | “19.232” | “9.633” |
| Total NPC-SS with hearing and ABR, change at Week 52, mean | “0.000” | “0.75” |
| Total NPC-SS with hearing and ABR, change at Week 52, SD | “1.000” | “4.500” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.3-7"></a>

###### Change in each NPC-SS domain at Week 52

| Domain, change from baseline at Week 52 | Sham control, mean | Sham control, SD | Adrabetadex, mean | Adrabetadex, SD |
| --- | --- | --- | --- | --- |
| Ambulation | “0.00” | “0.679” | “0.06” | “1.434” |
| Fine motor | “0.07” | “0.917” | “0.24” | “1.103” |
| Cognition | “-0.14” | “0.663” | “0.06” | “0.919” |
| Swallowing | “0.00” | “1.109” | “-0.29” | “1.360” |
| Memory | “0.00” | “0.784” | “0.18” | “1.218” |
| Speech | “0.14” | “0.663” | “-0.18” | “0.673” |
| Eye movement | “0.00” | “0.679” | “-0.06” | “0.547” |
| Hearing | “-0.22” | “1.302” | “1.14” | “1.236” |
| Seizures | “-0.50” | “1.286” | “-0.06” | “0.952” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.3-8"></a>

###### Post hoc cerebrospinal fluid biomarkers at Week 52 in adrabetadex-treated participants

> “At 52 weeks of treatment, nominally statistically significant increases in CSF 24(S)-OHC (27.7%; Figure 3) were observed, indicating adrabetadex increases neuronal cholesterol trafficking”
> “In addition, we observed nominally significant decreases in CSF levels of calbindin D (18.3%; Figure 4) and FABP3 (40.5%; Figure 5) over the same period”
> “27.7% increase from baseline at 52 weeks n=22 IQR (6.5%, 54.2%) P=0.0012”
> “18.3% decrease from baseline at 52 weeks n=24 IQR, –30.0%, 3.8% P=0.0117”
> “40.5% decrease from baseline at 52 weeks n=24 IQR, –69.4%, 0.0% P=0.0079”

Source: [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)

> “Results from a biomarker analysis of cerebrospinal fluid (CSF) samples banked during a previously completed Phase 2b/3 clinical trial show that adrabetadex addresses the core pathology of NPC and is associated with reductions in biomarkers of neuronal damage and cell death.”

Source: [Mandos Health survival and biomarker analyses press release (2025)](https://www.berentx.com/news/adrabetadex-data-analyses-show-benefit-npc/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### EQ-5D-3L visual analog scale at baseline and Week 52

| Time point | Sham control mean | Sham control SD | Adrabetadex mean | Adrabetadex SD |
| --- | --- | --- | --- | --- |
| Baseline | “71.9” | “16.28” | “68.3” | “19.97” |
| Week 52 | “73.2” | “13.04” | “75.7” | “19.00” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.4-2"></a>

###### Caregiver-rated CGIC responders at Week 52

> “CGIC Responders are defined as participants who received the caregiver's rating of no change, minimally improved, moderately improved, or markedly improved from baseline to Week 52.”

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

| Outcome | Sham control (n = 18) | Adrabetadex (n = 38) |
| --- | --- | --- |
| CGIC responders at Week 52, participants | “7” | “23” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Deaths, serious adverse events, and other adverse events by arm

| Event | Part A adrabetadex 900 mg | Part A adrabetadex 1200 mg | Part A adrabetadex 1800 mg | Part A sham | Part B adrabetadex 900 mg | Part B sham |
| --- | --- | --- | --- | --- | --- | --- |
| All-cause mortality | “0/3 (0.00%)” | “0/3 (0.00%)” | “1/3 (33.33%)” | “0/3 (0.00%)” | “0/29 (0.00%)” | “1/15 (6.67%)” |
| Any serious adverse event | “1/3 (33.33%)” | “0/3 (0.00%)” | “2/3 (66.67%)” | “0/3 (0.00%)” | “16/29 (55.17%)” | “3/15 (20.00%)” |
| Any other (non-serious) adverse event | “3/3 (100.00%)” | “3/3 (100.00%)” | “3/3 (100.00%)” | “3/3 (100.00%)” | “28/29 (96.55%)” | “14/15 (93.33%)” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.5-2"></a>

###### Serious adverse events of hearing, seizure, and aspiration in Part B

| Serious adverse event | Part B adrabetadex 900 mg | Part B sham |
| --- | --- | --- |
| Deafness | “3/29 (10.34%)” | “0/15 (0.00%)” |
| Hearing impaired | “3/29 (10.34%)” | “1/15 (6.67%)” |
| Seizure | “3/29 (10.34%)” | “1/15 (6.67%)” |
| Aspiration | “2/29 (6.90%)” | “1/15 (6.67%)” |
| Pneumonia aspiration | “3/29 (10.34%)” | “0/15 (0.00%)” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.5-3"></a>

###### Common non-serious adverse events in Part B

| Adverse event | Part B adrabetadex 900 mg | Part B sham |
| --- | --- | --- |
| Vomiting | “15/29 (51.72%)” | “2/15 (13.33%)” |
| Back pain | “14/29 (48.28%)” | “0/15 (0.00%)” |
| Fatigue | “12/29 (41.38%)” | “2/15 (13.33%)” |
| Pyrexia | “12/29 (41.38%)” | “3/15 (20.00%)” |
| Gait disturbance | “11/29 (37.93%)” | “2/15 (13.33%)” |
| Hypoacusis | “10/29 (34.48%)” | “0/15 (0.00%)” |
| Fall | “10/29 (34.48%)” | “1/15 (6.67%)” |
| Diarrhoea | “9/29 (31.03%)” | “1/15 (6.67%)” |
| Headache | “9/29 (31.03%)” | “1/15 (6.67%)” |
| Hearing impaired | “8/29 (27.59%)” | “6/15 (40.00%)” |
| Nausea | “8/29 (27.59%)” | “0/15 (0.00%)” |
| Ataxia | “7/29 (24.14%)” | “2/15 (13.33%)” |
| Tinnitus | “5/29 (17.24%)” | “0/15 (0.00%)” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.5-4"></a>

###### Company summary of safety in the Parts A and B safety population

| Event | Adrabetadex (n=38) | Sham control (n=18) |
| --- | --- | --- |
| Any TEAE, n (%) | “38 (100)” | “17 (94)” |
| Non-fatal treatment-emergent SAE, n (%) | “20 (53)” | “4 (22)” |
| Hearing impaired, serious, n (%) | “4 (11)” | “1 (6)” |
| Pneumonia, aspiration, serious, n (%) | “4 (11)” | “1 (6)” |
| Deafness, serious, n (%) | “3 (8)” | “0 (0)” |

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “Adverse events with ≥30% higher incidence in the adrabetadex-treated vs sham group included vomiting, hypoacusis, back pain, diarrhea, gait disturbance, and fatigue; treatment-related events with ≥30% higher incidence were vomiting, hypoacusis, back pain, and fatigue (Supplemental Table 3).”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: design limitations of Parts A and B

- Control and observed progression: Parts A and B compared intrathecal VTS-270 with a sham procedure of 1 to 2 small needle pricks on the lower back with no lumbar puncture. At Week 52 the mean change from baseline in the NPC-SS composite score was -0.1 (SD 1.55) in the sham group (n = 18) and 0.0 (SD 2.45) in the adrabetadex group (n = 38). The company stated that “Neither the VTS-270 nor the placebo arm showed disease progression”, and a data request summary states that the trial failed to show benefit “as the sham group had little progression” and that sham-controlled trials in NPC “are highly challenging due to variability of the disease”.
- Blinding: the participant, outcomes assessor, care provider, and investigator were blinded. The hearing rating was excluded from the efficacy score because the drug can cause hearing loss and “hearing information might have unblinded the NPC-SS raters to treatment status”. NPC-SS scores were generated by two central raters, which the inter-rater reliability study lists as a limitation.
- Sample size: the sample size was based on the potential number of available subjects for this ultra-rare disorder. The plan of approximately 51 subjects gave the ANCOVA 79% power under assumed 52-week increases of 0 to 0.2 points with VTS-270 and 1.6 to 1.9 points with sham. The statistical analysis plan states that 54 subjects were randomized; the prescribing information states that Parts A and B enrolled 56 treatment-naïve participants.
- Randomization ratio: one publication states that Part A randomized 12 subjects 1:1:1:1 to three dose levels or sham, and protocol amendment 15 states a 3:1 ratio in Part A. Both state a 2:1 ratio in Part B.
- Analysis sets: the registry analyzed 38 adrabetadex and 18 sham participants for the co-primary NPC-SS composite endpoint and 34 and 14 for the annualized slope. The prescribing information describes 32 participants who received up to 900 mg and 18 in the sham-control group. The statistical analysis plan restricts the modified intent-to-treat population to subjects who received at least one dose of 900 mg of VTS-270 or sham control, and the registry defines it as all randomized participants who received at least one treatment (sham or adrabetadex). The statistical analysis plan also changed the protocol's list of key secondary endpoints.
- Early exit: Part B participants with significant disease progression after 26 weeks or more could leave the blinded trial early and enter Part C; 2 sham and 2 adrabetadex participants qualified for this rescue option.
- Concomitant miglustat: randomization in Part B was stratified by miglustat use and baseline NPC-SS level, but the statistical analyses were not stratified. At baseline, 25 (66%) adrabetadex and 9 (50%) sham participants used miglustat. A post hoc analysis reported that subjects receiving miglustat, with or without adrabetadex, showed evidence of disease stabilization, while subjects receiving adrabetadex without miglustat showed disease worsening comparable to sham subjects not on miglustat.
- Biomarkers: cerebrospinal fluid was collected only from subjects receiving study drug; sham-control subjects provided urine and plasma. The post hoc biomarker study of 34 participants tested within-group changes with the Wilcoxon signed-rank test, with nominal significance at P<0.05 without adjustment for multiplicity.
- Sponsor statements: the company stated that it was evaluating this portion of the study “in order to ensure the data was properly captured and of the highest quality”. A community update stated that a manuscript summarizing the data and experience from the VTS-301 trial was being prepared.

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844); [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results); [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844); [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf); [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf); [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/); [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf); [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf); [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm); [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741); [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/)

<a id="topic-3.1.2.9-2"></a>

###### Little progression in the sham group

> “A phase 2b/3 one year sham controlled trial failed to show benefit as the sham group had little progression.”
> “In NPC, placebo/sham-controlled trials are highly challenging due to variability of the disease”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.2.9-3"></a>

###### Sponsor review of data quality after the result

> “The Company is in the process of evaluating this portion of the study in order to ensure the data was properly captured and of the highest quality.”

Source: [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)

<a id="topic-3.1.2.9-4"></a>

###### Two central raters

> “Limitations of this study include use of only two raters generating the NPC-SS scores.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="topic-3.1.2.9-5"></a>

###### No cerebrospinal fluid collection from sham-treated participants

> “Collect cerebrospinal fluid (CSF), urine, and plasma samples from the subjects receiving study drug, and urine and plasma samples from subjects randomized to sham control, will be collected at prespecified intervals and stored for exploratory biomarker analyses.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.9-6"></a>

###### Planned trial manuscript, May 2022

> “We are in the midst of putting together a manuscript for publication summarizing the data and experience from the VTS-301 trial, which we recognize as an important part of advancing understanding of the trial, of adrabetadex*, and of NPC1.”

Source: [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/)

<a id="heading-3.1.3"></a>

#### 3.1.3 VTS301 Part C

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Primary objective of Part C, before and after January 2021

> “The primary study objective in Part C is to evaluate the long-term safety, tolerability, and efficacy of VTS-270. Following a determination of a negative benefit/risk balance on 20 January 2021, the objective for Part C has been changed to evaluate only longer-term safety and tolerability.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.1-2"></a>

###### Registry statement of purpose

> “This study is to evaluate how safe and effective adrabetadex is for participants with Niemann-Pick Type C1 (NPC1) disease who experience neurologic symptoms (listed under Keywords).”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.1-3"></a>

###### Secondary objective: intrathecal access device substudy

> “Assess the safety and tolerability of the B. Braun Celsite Spinal Access Port utilized to administer VTS-270 (device safety and tolerability substudy).”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.1-4"></a>

###### VTS-270-302 primary objective

> “To evaluate the long-term safety and tolerability of adrabetadex in subjects transitioning from Study VTS301.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registry study dates and enrollment

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2015-12-23” |
| Primary completion (actual) | “2022-04-11” |
| Study completion (actual) | “2022-04-11” |
| Enrollment (actual) | “66” |
| Results first posted | “2023-08-29” |

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.2-2"></a>

###### Number of locations and facilities in Washington, DC and Switzerland

> “This study has 30 locations”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

| Country | Facility |
| --- | --- |
| United States | “Children's National Medical Center” |
| Switzerland | “INSELSPITAL, Universitätsspital Bern” |

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.2-3"></a>

###### Separate registration of Part C

> “Due to different study designs, the sponsor separated Part C into this separate registration (NCT04958642), leaving Parts A/B in NCT02534844.”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.2-4"></a>

###### End of dosing in 2021

> “Treatment with VTS-270 should be discontinued as soon as possible; in consideration of the need to determine a transition plan, treatment with VTS-270 will be permitted for up to an additional 9 months (20 October 2021).”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

> “The last doses for the VTS-301 study were administered and the study closeout process is well underway.”

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-3.1.3.2-5"></a>

###### VTS-270-302: registry dates and site in Costa Rica

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2019-12-02” |
| Study completion (actual) | “2021-10-18” |
| Enrollment (actual) | “2” |
| Location | “Hospital Clinica Biblica” |

Source: [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)

> “Any country may serve as a location for an activated study site, including but not limited to Costa Rica, Mexico, and China.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Open-label, single-group extension

> “Part C (NCT04958642) was an open-label extension that enrolled 66 patients including 35 LEMBAZ-treated patients from Parts A and B, 18 treatment-naïve, and 13 LEMBAZ-treated patients from Trial 2.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “In Part C, all participants will receive study drug.”
> “Participants in Part C will receive adrabetadex until the investigator considers adrabetadex to no longer be beneficial to the participant, or the development program is discontinued.”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.3-2"></a>

###### Efficacy endpoints planned for Part C

> “The change from baseline to each assessment in a composite outcome that is the sum of the ambulation, cognition, fine motor, and swallowing components of the NPC-SS”
> “Change from baseline in the EQ-5D-3L questionnaire at each assessment”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.3.3-3"></a>

###### Device substudies and termination of enrollment

> “A European site-specific substudy of the safety and tolerability of the device was conducted in subjects who met the eligibility criteria to have a device implanted for VTS-270 infusion.”
> “A European site-specific substudy of plasma and CSF PK of VTS-270 administered via the device was planned but not conducted under Part C, as no subjects consented.”
> “The VTS270 development program has been terminated by the sponsor. No new subjects are permitted to enroll in the study.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.3-4"></a>

###### VTS-270-302: open-label continuation study for VTS301 participants

> “This is a multicenter, multinational, open-label study of VTS-270 to evaluate the long-term safety and tolerability of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in participants transitioning from Study VTS301 (Parts A/B [NCT02534844] and Part C [NCT04958642]) with neurologic manifestations of Niemann-Pick Type C1 (NPC1) disease.”

Source: [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)

> “This study is intended as open-label treatment for approximately 7 subjects who completed Part B of Study VTS301.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Routes of entry into Part C

> “Subject has completed Part B, meets the criteria for dose reduction for a second time or meets the criteria for the rescue option”
> “Subject agrees to convert from the dose of VTS-270 currently receiving as a subject in the NIH phase 1/2a protocol to the dose chosen for Parts B and C of this study, 900 mg;”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “One of the following is required for inclusion into VTS301 Part C:”
> “Has agreed to convert from the monthly dosing regimen used in the NIH phase 1/2a protocol to an every 2 weeks dosing regimen”
> “The investigator has received prior written authorization from the sponsor for the participant to enter VTS301 Part C on an amended dose and/or regimen”
> “Has received prior written authorization from Vtesse to enroll directly into Part C”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.4-2"></a>

###### Conditions for continuing treatment after 21 June 2021

> “After 21 June 2021, subjects may not continue to receive IT adrabetadex, except for those subjects (and legally authorized representatives, as appropriate):”
> “who appear to be benefiting from intrathecal adrabetadex based on the investigator’s assessment, AND”
> “who are aware of the risks associated with adrabetadex, including hearing loss, and understand that no significant differences were seen between patients treated with adrabetadex and sham-treated patients on any efficacy measures in this randomized, controlled trial.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.4-3"></a>

###### VTS-270-302 inclusion criteria

> “Participant completed Part B of Study VTS301 (defined as having completed Visit 27/Week 52 or completed at least through Visit 13/Week 24 and required rescue option) and is continuing in Part C of Study VTS301.”
> “Participant, in the opinion of the Principal Investigator, should continue treatment with VTS-270.”

Source: [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Dosage in Part C

> “The LEMBAZ dosage was 900 mg intrathecally every two weeks.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “All participants receive their prescribed dose of adrabetadex. Dose is allowed to be adjusted down to a minimum of 400 milligrams (mg) or up to a maximum of 900 mg, at the investigator's discretion.”
> “Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.5-2"></a>

###### Dose re-escalation and reduction in Part C

> “If a subject has had his/her dose reduced and is in Part C on a tolerable dose, the subject may be dose titrated back up (e.g., from 400 mg to 600 mg and from 600 mg to 900 mg) to a tolerable dose as determined by the investigator.”
> “During Part C, the same guidelines apply for dose reduction, with each subject for whom dose reduction is considered being individually reviewed with the medical monitor.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.3.5-3"></a>

###### Dosing of participants from the NIH phase 1/2a trial

> “Rollover participants from Study 13-CH-0001 received adrabetadex at an amended dose and/or regimen after prior written authorization from the sponsor.”

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.5-4"></a>

###### Rationale for the intrathecal access port

> “Given that VTS-270 does not penetrate the blood-brain barrier and requires IT administration, the ability to administer VTS-270 via the device will obviate the need for biweekly lumbar punctures (LPs), as well as anesthesia, thereby removing a significant burden for subjects and site personnel.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.3.5-5"></a>

###### VTS-270-302 dosing

> “Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via LP infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the participant, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.”

Source: [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

Not applicable.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment

> “Part C may enroll more than 51 subjects.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.3.7.1-2"></a>

###### Participants analyzed by entry group

| Group | Participants analyzed |
| --- | --- |
| Treatment naive | “18” |
| Previously treated in phase I | “13” |
| Previously treated in Part A/B | “35” |
| Total | “66” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.7.1-3"></a>

###### VTS-270-302 planned sample size

> “The sample size for this study is approximately 7 subjects. The sample size was determined based on the potential number of subjects eligible to transition from Study VTS301.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Open-label population

> “The Open-label population included participants who received at least 1 dose of adrabetadex during Part C.”

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

> “The Part C open‐label population will consists of all subjects who receive at least one dose of VTS‐270 during Part C.”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Participant flow and reasons for not completing

| Milestone or reason | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
| --- | --- | --- | --- |
| Started | “18” | “13” | “35” |
| Completed | “0” | “0” | “0” |
| Not completed | “18” | “13” | “35” |
| Adverse event | “1” | “0” | “1” |
| Death | “0” | “0” | “1” |
| Investigator's decision | “0” | “0” | “1” |
| Lost to follow-up | “1” | “0” | “0” |
| Termination by sponsor or regulatory authorities | “8” | “4” | “13” |
| Transferred to EAP following study termination | “0” | “0” | “1” |
| Transferred to Expanded Access Program | “1” | “0” | “0” |
| Transferred to OLEX program | “3” | “0” | “5” |
| Withdrawal by subject | “4” | “9” | “13” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

###### Sources of Part C participants

> “Participants who completed Part B and participants who completed National Institutes of Health (NIH) phase 1 study (Protocol 13-CH-0001) were eligible to participate in this study.”

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.1-3"></a>

###### Recorded reason the study stopped

| Field | Quoted record |
| --- | --- |
| Why stopped | “Terminated by previous Sponsor decision” |

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.8.1-4"></a>

###### VTS-270-302 disposition

> “The study has been terminated early by the Sponsor due to previous Sponsor decision.”

Source: [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline demographics by entry group

| Characteristic | Treatment naive (n = 18) | Previously treated in phase I (n = 13) | Previously treated in Part A/B (n = 35) | Total (n = 66) |
| --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “13.2(5.07)” | “17.5(6.16)” | “14.1(5.60)” | “14.5(5.70)” |
| Female | “10” | “7” | “15” | “32” |
| Male | “8” | “6” | “20” | “34” |
| White | “16” | “13” | “29” | “58” |
| Hispanic or Latino | “3” | “1” | “2” | “6” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.2-2"></a>

###### VTS-270-302 baseline reporting

> “No data is reported here to maintain participant confidentiality.”

Source: [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Efficacy endpoints not reported after January 2021

> “Part C: After 20 January 2021, efficacy endpoints for Part C will not be reported.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.8.3-2"></a>

###### VTS-270-302: efficacy assessments discontinued

> “Efficacy assessments will not be performed and existing efficacy data will not be analyzed.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Primary outcome: participants with TEAEs and SAEs

| Outcome | Treatment naive (n = 18) | Previously treated in phase I (n = 13) | Previously treated in Part A/B (n = 35) |
| --- | --- | --- | --- |
| Any TEAEs | “18” | “13” | “34” |
| SAEs | “9” | “7” | “20” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.5-2"></a>

###### Deaths and serious adverse events

| Event | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
| --- | --- | --- | --- |
| All-cause mortality | “1/18 (5.56%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Any serious adverse event | “9/18 (50.00%)” | “7/13 (53.85%)” | “20/35 (57.14%)” |
| Dysphagia | “1/18 (5.56%)” | “0/13 (0.00%)” | “4/35 (11.43%)” |
| Pneumonia aspiration | “1/18 (5.56%)” | “0/13 (0.00%)” | “3/35 (8.57%)” |
| Pneumonia | “1/18 (5.56%)” | “2/13 (15.38%)” | “1/35 (2.86%)” |
| Back pain | “3/18 (16.67%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Deafness neurosensory | “1/18 (5.56%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Meningitis bacterial | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Meningitis staphylococcal | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Spinal subdural haematoma | “1/18 (5.56%)” | “0/13 (0.00%)” | “0/35 (0.00%)” |
| Spinal subarachnoid haemorrhage | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Device dislocation | “0/18 (0.00%)” | “0/13 (0.00%)” | “2/35 (5.71%)” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.5-3"></a>

###### Common non-serious adverse events

| Adverse event | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
| --- | --- | --- | --- |
| Any other (non-serious) adverse event | “18/18 (100.00%)” | “13/13 (100.00%)” | “34/35 (97.14%)” |
| Vomiting | “12/18 (66.67%)” | “9/13 (69.23%)” | “16/35 (45.71%)” |
| Hypoacusis | “9/18 (50.00%)” | “4/13 (30.77%)” | “9/35 (25.71%)” |
| Headache | “9/18 (50.00%)” | “9/13 (69.23%)” | “12/35 (34.29%)” |
| Ataxia | “9/18 (50.00%)” | “2/13 (15.38%)” | “8/35 (22.86%)” |
| Fatigue | “8/18 (44.44%)” | “5/13 (38.46%)” | “13/35 (37.14%)” |
| Pyrexia | “6/18 (33.33%)” | “9/13 (69.23%)” | “17/35 (48.57%)” |
| Fall | “5/18 (27.78%)” | “7/13 (53.85%)” | “16/35 (45.71%)” |
| Gait disturbance | “2/18 (11.11%)” | “6/13 (46.15%)” | “10/35 (28.57%)” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.5-4"></a>

###### Termination of device implantation after catheter tip migration

> “Device implantations were terminated in August 2018 following reports of the catheter tip migrating from the IT space in some subjects.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.8.5-5"></a>

###### VTS-270-302 safety

| Outcome | Adrabetadex (n = 2) |
| --- | --- |
| All TEAEs, participants | “2” |
| SAEs, participants | “0” |
| All-cause mortality | “0/2 (0.00%)” |

Source: [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: design limitations of Part C

- Control and blinding: Part C was an open-label extension in which all participants received study drug, and the sponsor gave it a separate registration because of its different study design.
- Mixed population and dosing: Part C enrolled 66 participants, comprising 35 LEMBAZ-treated participants from Parts A and B, 18 treatment-naïve participants, and 13 LEMBAZ-treated patients from Trial 2. The dose could be adjusted between 400 mg and 900 mg at the investigator's discretion, and rollover participants from Study 13-CH-0001 received an amended dose and/or regimen.
- Missing efficacy collection: the planned efficacy endpoints included the NPC-SS composite and the EQ-5D-3L. Following a determination of a negative benefit/risk balance on 20 January 2021, the objective of Part C was changed to longer-term safety and tolerability only, and efficacy endpoints after 20 January 2021 were not reported.
- Early termination: the sponsor discontinued the development program and terminated Part C. No participant completed the study (0 of 18 treatment-naive, 0 of 13 previously treated in phase I, and 0 of 35 previously treated in Part A/B); termination by sponsor or regulatory authorities accounted for 8, 4, and 13 participants and withdrawal by subject for 4, 9, and 13.
- Selective continuation: after 21 June 2021, only subjects who appeared to be benefiting in the investigator's assessment, and who understood that no significant differences were seen between adrabetadex and sham on any efficacy measure in the randomized trial, could continue treatment.
- Substudies: the planned European plasma and CSF pharmacokinetic substudy of administration through the device was not conducted because no subjects consented.
- VTS-270-302 continuation study: planned for approximately 7 subjects, it enrolled 2, was terminated early by the sponsor, did not perform efficacy assessments or analyze existing efficacy data, and reported no baseline data to maintain participant confidentiality.

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642); [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results); [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf); [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf); [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf); [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655); [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results); [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.3.9-2"></a>

###### Termination of Part C by the sponsor

> “The development program for adrabetadex was discontinued and Part C of the study was terminated by the Sponsor.”

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

> “The Sponsor has discontinued the VTS-270 development program following determination of a negative benefit/risk balance.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="heading-3.1.4"></a>

#### 3.1.4 VTS-270-001

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Registered objective: long-term safety and effectiveness

> “Information will be collected about long-term safety and effectiveness of adrabetadex shots in the spine every 2 weeks.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.1-2"></a>

###### Protocol primary and secondary objectives

| Objective | Protocol text |
| --- | --- |
| Primary objective | “To evaluate the longer-term safety and tolerability of adrabetadex administered IT via LP every 2 weeks” |
| Secondary objective | “To summarize additional longer-term safety and tolerability of adrabetadex administered IT via LP every 2 weeks” |

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registry study dates

| Field | Registry record |
| --- | --- |
| Study start (actual) | “2018-06-18” |
| Primary completion (actual) | “2021-11-02” |
| Study completion (actual) | “2021-11-02” |
| First posted | “2018-08-23” |
| Results first posted | “2024-01-17” |

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.2-2"></a>

###### Study sites in the United States

> “This study has 17 locations”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

| Facility | Location |
| --- | --- |
| “University of Arkansas System” | “Little Rock, Arkansas, United States, 72205” |
| “Loma Linda University Health System” | “Loma Linda, California, United States, 92354” |
| “Children's Hospital Los Angeles” | “Los Angeles, California, United States, 90027” |
| “Children's Hospital of Orange County” | “Orange, California, United States, 92868” |
| “Children's Hospital Colorado” | “Aurora, Colorado, United States, 80045” |
| “Children's National Hospital” | “Washington D.C., District of Columbia, United States, 20010” |
| “Rare Disease Research, LLC” | “Atlanta, Georgia, United States, 30318” |
| “Rush University Medical Center” | “Chicago, Illinois, United States, 60612” |
| “Gillette Children's Specialty Healthcare” | “Saint Paul, Minnesota, United States, 55101” |
| “Children's Specialty Center of Nevada” | “Las Vegas, Nevada, United States, 89109” |
| “NYU Langone Medical Center” | “New York, New York, United States, 10017” |
| “Cincinnati Children's Hospital Medical Center” | “Cincinnati, Ohio, United States, 45229” |
| “Oregon Health & Science University” | “Portland, Oregon, United States, 97239” |
| “The Children's Hospital at TriStar Centennial” | “Nashville, Tennessee, United States, 37203” |
| “Vanderbilt University Medical Center” | “Nashville, Tennessee, United States, 37232” |
| “Dell Children's Medical Center of Central Texas” | “Austin, Texas, United States, 78723” |
| “Carilion Medical Center, Carilion Clinic” | “Roanoke, Virginia, United States, 24014” |

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.2-3"></a>

###### Protocol dates and end of treatment in October 2021

| Field | Protocol text |
| --- | --- |
| Original protocol | “Date of Original Protocol: 01 December 2017” |
| Protocol amendment 3 | “Date of Protocol Amendment 3: 23 June 2021” |

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

> “Following a determination of a negative benefit/risk balance by the Sponsor, treatment will be allowed to continue up to 20 October 2021.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Open-label single-arm trial in treatment-naive and previously treated participants

> “Trial 3 (NCT03643562) was a non-randomized, open-label, single-arm trial that enrolled 27 patients (9 treatment-naïve, 18 previously treated through expanded access program) with neurological manifestations of NPC between 4 and 43 years of age.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.4.3-2"></a>

###### Registry design fields and conversion from expanded access

> “This study was amended from expanded access to a clinical trial.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

| Field | Registry record |
| --- | --- |
| Official title | “Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC)” |
| Other study ID | “VTS-270-001” |
| Study type | “Interventional” |
| Phase | “Phase 3” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “Continued treatment for children at least 4 years of age” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.3-3"></a>

###### Protocol design: prospective open-label safety study without a control group

> “This is a prospective, open-label study to evaluate the longer-term safety of adrabetadex in subjects with neurological symptoms of NPC type C disease.”
> “No control product will be used in the study.”
> “No data monitoring committee will be used in this study.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.3-4"></a>

###### Protocol amendment 3: sponsor recommendation to discontinue treatment and benefit assessment for continuation

> “Effective 20 January 2021, Mallinckrodt is recommending that treatment with adrabetadex be discontinued as soon as possible with appropriate clinician oversight.”
> “In recognition of the complexity of patient care, Mallinckrodt will make adrabetadex available for up to 9 months to allow time for the physician and subject/family to develop a transition plan.”
> “For subjects continuing in this study after 21 June 2021, the investigator must assess whether the subject is benefiting from treatment with adrabetadex.”
> “Subjects must be discontinued from the study if the investigator does not consider them to be benefiting from treatment and/or they do not understand the risks associated with adrabetadex, including hearing loss.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Registry inclusion criteria

> “Is male or female and at least 4 years of age at time of screening.”
> “Has a confirmed diagnosis of NPC and exhibits neurologic symptoms.”
> “Has the ability to undergo LP and IT drug administration.”
> “If taking miglustat (Zavesca®), must have been on a stable dose for the past 6 weeks and be willing to remain on a stable dose for the duration of participation in the study, or discontinue miglustat use at least 6 weeks before entry into the study (Day 1).”
> “If has a history of seizures, the condition is adequately controlled as per protocol requirements.”
> “Agrees to discontinue any investigational treatments (other than adrabetadex) for at least 1 month before first dose on Day 1.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.4-2"></a>

###### Registry exclusion criteria

> “Weighs less than 15 kg.”
> “Has a history of hypersensitivity reactions to any product containing 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) or has a history of hypersensitivity reactions or allergy to anesthesia/sedation.”
> “Has received treatment with any investigational product (other than adrabetadex) within 1 month prior to Day 1 of treatment.”
> “Has systemic infection or uncontrolled psychosis.”
> “Has known history of a bleeding disorder.”
> “Has used anticoagulants within 2 months of entry into the study.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.4-3"></a>

###### Protocol criteria for participants already receiving adrabetadex and for hydrocephalus

> “If not currently receiving adrabetadex, agrees to discontinue any other investigational treatments for at least 1 month prior to first dose of adrabetadex (Day 1); subjects who are currently receiving intrathecal adrabetadex are eligible to participate.”
> “Has evidence of obstructive hydrocephalus or normal pressure hydrocephalus.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Starting dosage by prior treatment status

> “Treatment-naïve patients started at LEMBAZ 400 mg intrathecally every two weeks, while patients already receiving LEMBAZ continued at their current stable dosage intrathecally every two weeks.”
> “The Trial 3 duration was open-ended; mean (SD) duration of LEMBAZ treatment was 75 (36) weeks.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.4.5-2"></a>

###### Registry arm description and treatment duration

> “Participants will receive prescribed adrabetadex by intra-thecal (IT) injection every 2 weeks.”
> “Participants who were already taking adrabetadex will receive their stable dose. Participants who have not ever taken it will start by receiving 400 mg.”
> “Participants will receive treatment every 2 weeks until their doctor finds it does not help them anymore, they withdraw, or the study is stopped for any reason.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.5-3"></a>

###### Protocol dose preparation and lumbar puncture administration

> “The total infusion volume should be 10 mL; to achieve a final total volume of 10 mL, 0.9% sterile sodium chloride for injection, USP should be added to the adrabetadex solution.”
> “Adrabetadex will be administered as an IT slow bolus (1 to 2 minutes, depending on the volume administered) LP injection (maximum rate of administration = 4.5 mL/minute).”
> “Prior to the adrabetadex injection, a volume of cerebrospinal fluid approximately equal to the infusion volume (approximately 10 mL) will be removed.”
> “Patients will be required, if possible, to lie flat with feet elevated for 30 to 45 minutes following dosing.”
> “For the 3 days following each procedure, subjects should avoid acoustic overstimulation and minimize exposure to loud noises, eg, headphones for music or video games.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.5-4"></a>

###### Protocol dose adjustment rules and dose increases stopped in April 2021

> “Patients who, in the opinion of the clinician, experience a drug-related adverse event (AE) after any IT treatment that is considered clinically relevant and impactful to the subject’s function may have their dose reduced back to the previously tolerated dose.”
> “The lowest dose is 400 mg; subjects unable to tolerate 400 mg will be discontinued from the study.”
> “Effective as of the date of Amendment 2 (21 April 2021), subjects will remain at their current dose or their dose may be decreased for tolerability reasons.”
> “There are no adjustments of dosing regimen for weight or subject age.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.5-5"></a>

###### Protocol concomitant medication restrictions

> “Use of anticoagulants is prohibited during the study.”
> “The use of other investigational medications and treatments is also prohibited.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary outcome measure

| Field | Registry record |
| --- | --- |
| Outcome measure | “Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)” |
| Time frame | “Baseline up to Week 134” |

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.6.1-2"></a>

###### Registry definition of treatment-emergent and serious adverse events

> “A TEAE was defined as an AE with onset on or after the start of adrabetadex treatment.”
> “Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.”

Source: [ClinicalTrials.gov NCT03643562 API record](https://clinicaltrials.gov/api/v2/studies/NCT03643562)

<a id="topic-3.1.4.6.1-3"></a>

###### Protocol primary and secondary safety endpoints

| Endpoint | Protocol text |
| --- | --- |
| Primary endpoint | “Summary of TEAEs, SAEs, discontinuation due to TEAEs, and deaths” |
| Secondary endpoint | “Change in audiologic testing.” |
| Secondary endpoint | “Laboratory changes from baseline (hematology, chemistry, coagulation, urinalysis.)” |
| Secondary endpoint | “Vital sign measurements.” |

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.6.1-4"></a>

###### Protocol definition of a clinically significant hearing change

| Criterion | Protocol text |
| --- | --- |
| Single frequency | “≥20 dB increase at any one test frequency relative to baseline measure.” |
| Adjacent frequencies | “≥10 dB increase at any two adjacent test frequencies relative to baseline measure.” |
| Loss of response | “Loss of response at three consecutive test frequencies where responses were previously obtained (specifically the highest frequencies tested) on baseline measure.” |

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

> “As of 20 January 2021, ABRs will not be collected, as the potential risks with the procedure outweigh the potential benefit of the data.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment and enrollment closure in January 2021

> “The study is anticipated to enroll approximately 60 subjects from 30 sites in the US.”
> “Effective 20 January 2021, no new subjects can be enrolled in the study.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Actual enrollment and participants analyzed by group

| Field | Treatment naive | Previously treated | Total |
| --- | --- | --- | --- |
| Overall number of baseline participants | “9” | “18” | “27” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Registry analysis population for baseline, outcome, and adverse event data

| Field | Registry record |
| --- | --- |
| Baseline, outcome, and adverse event analysis population | “All enrolled participants” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="topic-3.1.4.7.2-2"></a>

###### Protocol statistical methods: descriptive statistics without imputation

> “Study data will be summarized using descriptive statistics.”
> “No hypothesis testing will be conducted.”
> “All analyses will be based on available data.”
> “Missing data will not be imputed.”
> “Data generated in this study may be pooled with others in the adrabetadex clinical program or from historical cohort for comparison.”
> “Treatment-emergent AEs (TEAEs) are defined as those AEs that are not present at Day 1 of study or represent the exacerbation of a pre-existing condition during the treatment period.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Registry participant flow and reasons for not completing

| Milestone or reason | Treatment naive | Previously treated |
| --- | --- | --- |
| Started | “9” | “18” |
| Received at least 1 dose of study drug | “9” | “18” |
| Completed | “1” | “2” |
| Not completed | “8” | “16” |
| Adverse event | “1” | “0” |
| Lack of efficacy | “0” | “1” |
| Other than specified | “3” | “2” |
| Physician decision | “0” | “1” |
| Study terminated by sponsor | “2” | “10” |
| Withdrawal by subject | “2” | “2” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Registry baseline demographics

| Characteristic | Treatment naive (n=9) | Previously treated (n=18) | Total (n=27) |
| --- | --- | --- | --- |
| Age, mean (SD), years | “12.33(8.718)” | “17.94(13.705)” | “16.07(12.388)” |
| Female, participants | “4” | “7” | “11” |
| Male, participants | “5” | “11” | “16” |
| Hispanic or Latino, participants | “1” | “0” | “1” |
| White, participants | “7” | “17” | “24” |
| Black or African American, participants | “0” | “1” | “1” |
| Race unknown or not reported, participants | “2” | “0” | “2” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Efficacy and patient-reported outcome assessments not collected under the amended protocol

> “Efficacy assessments (NPC-severity scale [NPC-SS], Clinician Clinical Global Impression of Change [CGIC]) and self-reported outcomes (EuroQol five-dimensional three-level version [EQ-5D-3L]) will not be collected or analyzed.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Primary outcome: participants with treatment-emergent and serious adverse events

| Outcome | Treatment naive (n=9) | Previously treated (n=18) |
| --- | --- | --- |
| All TEAEs, participants | “9” | “17” |
| SAEs, participants | “5” | “9” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="topic-3.1.4.8.5-2"></a>

###### All-cause mortality and serious adverse events by preferred term

| Event | Treatment naive | Previously treated |
| --- | --- | --- |
| All-cause mortality | “0/9 (0.00%)” | “0/18 (0.00%)” |
| Any serious adverse event | “5/9 (55.56%)” | “9/18 (50.00%)” |
| Deafness | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Pneumonia | “1/9 (11.11%)” | “2/18 (11.11%)” |
| Pneumonia aspiration | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Acute respiratory failure | “2/9 (22.22%)” | “0/18 (0.00%)” |
| Respiratory distress | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Hypoxia | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Meningitis | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Staphylococcal bacteraemia | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Seizure | “1/9 (11.11%)” | “3/18 (16.67%)” |
| Ataxia | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Sedation | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Vomiting | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Post procedural haemorrhage | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Femur fracture | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Acute kidney injury | “0/9 (0.00%)” | “1/18 (5.56%)” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="topic-3.1.4.8.5-3"></a>

###### Selected other (non-serious) adverse events reported at a 5% frequency threshold

| Event | Treatment naive | Previously treated |
| --- | --- | --- |
| Any other adverse event | “9/9 (100.00%)” | “17/18 (94.44%)” |
| Hypoacusis | “2/9 (22.22%)” | “4/18 (22.22%)” |
| Deafness | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Deafness neurosensory | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Fatigue | “6/9 (66.67%)” | “7/18 (38.89%)” |
| Ataxia | “5/9 (55.56%)” | “6/18 (33.33%)” |
| Vomiting | “4/9 (44.44%)” | “4/18 (22.22%)” |
| Headache | “3/9 (33.33%)” | “2/18 (11.11%)” |
| Back pain | “3/9 (33.33%)” | “0/18 (0.00%)” |
| Pyrexia | “3/9 (33.33%)” | “3/18 (16.67%)” |
| Somnolence | “0/9 (0.00%)” | “4/18 (22.22%)” |
| Seizure | “2/9 (22.22%)” | “1/18 (5.56%)” |
| Upper respiratory tract infection | “3/9 (33.33%)” | “8/18 (44.44%)” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: design limitations of VTS-270-001

- Control and blinding: VTS-270-001 was a non-randomized, open-label, single-arm trial with masking recorded as none; the protocol used no control product and no data monitoring committee.
- Sample size and population: the protocol anticipated approximately 60 subjects from 30 sites, and no new subjects could enroll after 20 January 2021. The trial enrolled 27 participants (9 treatment-naïve and 18 previously treated through the expanded access program) aged 4 to 43 years. Treatment-naïve participants started at 400 mg, previously treated participants continued at their current stable dosage, and dose increases stopped as of Amendment 2 (21 April 2021).
- Missing efficacy collection: under the amended protocol, efficacy assessments (NPC-SS and clinician CGIC) and the EQ-5D-3L were not collected or analyzed, and auditory brainstem responses were not collected as of 20 January 2021.
- Analysis: data were summarized with descriptive statistics, with no hypothesis testing and no imputation of missing data.
- Early termination: the trial was terminated early when the sponsor determined that the benefit-risk profile of adrabetadex was not favorable, and treatment was allowed to continue up to 20 October 2021. Of 27 participants, 1 treatment-naive and 2 previously treated participants completed; study termination by the sponsor accounted for 2 and 10 participants. After 21 June 2021, continuation required the investigator to assess that the subject was benefiting from treatment.
- Sponsor statements: the protocol states that a comprehensive evaluation of all available clinical data “shows no clear evidence of benefit of adrabetadex in the treatment of neurologic symptoms of NPC” and that “the benefit/risk balance is negative.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562); [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results); [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.9-2"></a>

###### Registry limitations and caveats: early termination

> “This study was terminated early when the Sponsor had determined that the benefit-risk profile of adrabetadex was not favorable and the clinical development program for adrabetadex was discontinued.”

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="topic-3.1.4.9-3"></a>

###### Prior sponsor's benefit-risk conclusion stated in the protocol, June 2021

> “Although there are case reports from a few expert treating physicians indicating a potential benefit of adrabetadex in NPC patients treated over a period of time, a comprehensive evaluation of all available clinical data shows no clear evidence of benefit of adrabetadex in the treatment of neurologic symptoms of NPC.”
> “In view of established risks of treatment with adrabetadex, Mallinckrodt concludes that the benefit/risk balance is negative.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.5"></a>

#### 3.1.5 Expanded Access Program

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Purpose of the original Rush expanded access protocol

> “The protocol was developed to allow access to treatment for 001-01, who was showing relatively rapid disease progression and could not enroll in the phase 1/2a trial.”
> “In this study, the long-term effects of intrathecal HPβCD treatment for 2.5–3 years in humans with NPC were evaluated.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.1-2"></a>

###### Objective of the survival analysis by baseline disease burden

> “To evaluate overall survival among individuals with I-NPC treated with adrabetadex and an untreated cohort, stratified by baseline disease burden.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.1-3"></a>

###### Objective of the prompt versus delayed treatment analysis

> “This analysis evaluates outcomes in participants with I-NPC receiving prompt versus delayed adrabetadex treatment following diagnosis.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.1-4"></a>

###### Objective of the combination therapy analysis

> “To describe baseline characteristics, treatment sequencing, safety outcomes, and combination therapy patterns in a cohort of participants treated with adrabetadex plus arimoclomol and/or levacetylleucine in an adrabetadex expanded access program (EAP), and to evaluate evidence of an emerging combination treatment paradigm in NPC.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Expanded access protocol under IND 119856 at Rush University Medical Center, with drug provided by Mandos Health

> “Intrathecal adrabetadex was administered under an expanded access protocol (IND 119856) and reliance agreement with NIH approved by the Rush University Medical Center IRB.”
> “EBK has received funds to consult and/or run clinical trials for commercial programs focused in NPC including Orphazyme, Zevra, Intrabio, Vtesse, Sucampo, Mallinckrodt, and runs an expanded access program for adrabetadex for which drug is provided by Mandos Health.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.2-2"></a>

###### Program start in 2013

> “Individuals with I-NPC were eligible to participate in an intrathecal adrabetadex expanded access program (EAP) that was initiated in 2013.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.2-3"></a>

###### Institutional review board approval of the original protocol

> “The Rush University Medical Center IRB approved the protocol, and legal guardians of all subjects signed informed consent.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.2-4"></a>

###### Evaluation sites for expanded access participants in a biomarker study

> “For the EAP participants in this analysis, evaluations were conducted at RUSH University Medical Center, Yale University, or University of California Los Angeles (UCLA).”

Source: [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)

<a id="topic-3.1.5.2-5"></a>

###### Active and pending sites, December 2021

> “14 distinct sites are currently active in EAP”
> “5 pending new sites for EAP”

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-3.1.5.2-6"></a>

###### Agreement with the FDA to continue the program beyond October 2021

> “We are thrilled today to announce that we’ve reached agreement with the FDA to officially continue the US Expanded Access Program (EAP) for intrathecal administration of adrabetadex”
> “beyond October 20th, 2021.”

Source: [Mandos expanded access program continuation letter (2021)](https://www.berentx.com/news/npc-expanded-access-program-continues-september-2021/)

<a id="topic-3.1.5.2-7"></a>

###### Data cutoff of the combination therapy analysis

> “Data analysis cut-off date is March 27, 2026.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Label description of the expanded access program data

> “The expanded access program data included 85 patients with neurological manifestations of NPC between 1 and 43 years of age (mean age was 12 years) who were treatment-naïve (71 patients) or previously treated (14 patients) under Trials 1, 2, and 3.”
> “The duration of the expanded access program was open-ended; mean (SD) duration of treatment with LEMBAZ was 44 (32) months.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.5.3-2"></a>

###### Intermediate-size patient population IND modeled on the phase 1/2a trial

> “In order to treat her brother, 001-02, at the same time, the expanded access application was submitted to FDA as an intermediate-size patient population IND (IND 119856).”
> “The protocol was designed to parallel the ongoing phase 1/2a trial, with 2-week dosing intervals as opposed to the 4-week intervals in the phase 1/2a trial.”
> “We report here results from three patients treated with IT HPβCD via expanded access through an intermediate-size patient population IND.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.3-3"></a>

###### Safety data collection in the combination therapy analysis

> “Safety data were not available for patients receiving other NPC therapies prior to study enrollment.”
> “Safety data were only collected while participants were in the study and receiving adrabetadex.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.3-4"></a>

###### Prompt versus delayed treatment analysis of participants treated for at least 5 years

> “The EAP population was surveyed for participants with disease onset <6 years of age and who had sustained treatment for ≥5 years.”
> “Change from baseline in R4DNPCCSS score was summarized for participants treated with adrabetadex within <1 year (prompt treatment) versus ≥1 year (delayed treatment) from neurological onset.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.3-5"></a>

###### Survival analysis of pooled clinical study and expanded access participants by baseline disease burden

> “This analysis evaluated overall survival in adrabetadex-treated participants with I-NPC stratified by baseline disease burden using a rescored 4-domain NPC Clinical Severity Scale (R4DNPCCSS).”
> “Overall survival was estimated using the Kaplan–Meier (KM) method for the adrabetadex-treated participants and for an untreated cohort from the National Institutes of Health (NIH) natural history study of NPC.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.3-6"></a>

###### Sibling case report design

> “Disease progression before and after adrabetadex initiation was monitored using the Rescored 4-domain Niemann-Pick disease type C Clinical Severity Scale (R4DNPCCSS), a disease-specific clinical severity scale which assesses ambulation, fine motor skills, speech, and rescored swallowing.”
> “Qualitative physician assessments were performed at each visit.”

Source: [Julich et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Julich_2026_CNS-Poster_Sibling-Case-Study_09Oct2026_Final-1.pdf)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Ineligibility for enrolling clinical trials

> “Enrollment in the EAP was initiated in 2013 and required that participants be ineligible for all currently enrolling clinical trials.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.4-2"></a>

###### Access for patients unable to enroll in trials

> “These protocols included a natural history/observational study (NCT00344331), phase I/II and phase II/III studies of intrathecal VTS‐270/adrabetadex (NCT01747135 and NCT02534844), and an expanded access program for access to intrathecal VTS‐270/adrabetadex for patients with NPC1 who were unable to enroll in trials (IND 119856).”

Source: [Cawley et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11893204/)

<a id="topic-3.1.5.4-3"></a>

###### Trial ineligibility of the first three expanded access patients

> “At age 13 she screened for the phase 1/2a trial of IT HPβCD but was ineligible due to multiple anticonvulsants and vagal nerve stimulator use.”
> “He was not able to enter the phase 1/2a trial.”
> “001-03 could not enter the phase 1/2a trial of HPβCD as it was closed when the family requested screening.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.4-4"></a>

###### Continued-benefit criteria for participants leaving the VTS301 trial, December 2021

> “We were thrilled to be able to support the patients who wanted to continue with their adrabetadex treatments following the conclusion of their clinical trial participation.”
> “We are most appreciative for the preparation and vigilance from everyone involved with the Expanded Access Program (EAP) who enabled those patients who met the eligibility criteria for continued benefit to enroll into the expanded access program and continue treatment without interruption.”

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-3.1.5.4-5"></a>

###### Supply per FDA risk-benefit criteria, November 2022

> “We want to reinforce that we will continue to provide adrabetadex for the North American Expanded Access Program (EAP) per the criteria regarding risk/benefit from FDA.”

Source: [Mandos November 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-november-2022/)

<a id="topic-3.1.5.4-6"></a>

###### Age criteria expanded to 3 months to 25 years, September 2024

> “Recently, after discussions with the FDA, the EAP age criteria have been expanded to include patients from 3 months to 25 years old.”

Source: [Beren Therapeutics September 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-september-2024/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Label dosing in the expanded access program

> “Treatment-naïve patients were dosed intrathecally every two weeks at a starting intrathecal LEMBAZ dosage of 200 mg (less than 4 years of age) or 400 mg (4 years of age or older).”
> “The LEMBAZ dosage was increased to a maximum of 600 mg (for patients who weighed 7 to 12 kg) or 900 mg (for patients who weighed more than 12 kg) every two weeks.”
> “Patients already receiving LEMBAZ continued at their current stable dosage.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.5.5-2"></a>

###### Titration ceilings of the initial and revised expanded access protocols

> “In the EAP, the adrabetadex dose started at 200 mg or 400 mg based on age every 2 weeks with stepwise titration up to 1200 mg in the initial protocol or 900 mg in the later revision, and dose adjustments were allowed.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.5-3"></a>

###### Formulation, route, and dose range of the original Rush protocol

> “A formulation of HPβCD with a specific chemical fingerprint was obtained from Janssen Research & Development, LLC initially and then Vtesse, Inc. (VTS-270, same formulation) and in all cases was administered by intrathecal infusion via lumbar puncture every two weeks.”
> “The initial protocol was written to dose escalate from 200 mg to 400 mg (accepted dose range at the time) over 4 months based on safety.”
> “The protocol was amended to allow dosing based on tolerability within a range from 200 mg-1200 mg.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.5-4"></a>

###### Doses and dosing intervals in a long-term treated cohort

> “Intrathecal doses of adrabetadex at the time of sample collection ranged from 300–900 mg (mean 660 ± 216 mg).”
> “Interval between doses was either 2 weeks (n=6) or 4 weeks (n=4).”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.5-5"></a>

###### Doses in the sibling case report

> “She subsequently enrolled in an Expanded Access Program (EAP) and continued to receive adrabetadex.”
> “Sibling A currently receives adrabetadex 500 mg Q2W in the EAP.”
> “Sibling B initiated intrathecal adrabetadex in the EAP approximately 10 months after neurological symptom onset, at an initial dose of 200 mg Q2W.”
> “Sibling B currently receives adrabetadex 500 mg Q2W in the EAP.”

Source: [Julich et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Julich_2026_CNS-Poster_Sibling-Case-Study_09Oct2026_Final-1.pdf)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Rescored 4-domain NPC Clinical Severity Scale as the Disease Progression Outcome

<a id="topic-3.1.5.6.1-1"></a>

###### Domains of the rescored 4-domain scale and burden quartiles

> “The R4DNPCCSS is a modified version of the 5-domain NPCCSS, which includes the domains most relevant to patients, caregivers, and clinicians: ambulation, swallowing, cognition, speech, and fine-motor.”
> “The R4DNPCCSS eliminates the cognitive domain and adds an improved swallow scoring algorithm.”
> “Baseline R4DNPCCSS scores (0–20 composite score; higher scores indicate greater impairment) were used to stratify participants into disease burden groups defined by quartiles (minimal [≤4], mild [5 to 8], moderate [9 to 12], severe [≥13]).”
> “This analysis was updated from tertiles to quartiles to better reflect NPC disease characteristics.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.6.1-2"></a>

###### Hearing items excluded from severity scores because of cyclodextrin ototoxicity

> “Hearing items were scored at baseline to evaluate disease severity, but efficacy assessment scores excluded hearing and auditory brainstem response items, as hearing loss is a known side effect of HPβCD.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

> “The hearing domain was removed due to the known ototoxicity of 2HPβCD.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Participants enrolled, December 2021

| Field | Dashboard |
| --- | --- |
| Current patients enrolled in Expanded Access Program | “50 patients” |

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-3.1.5.7.1-2"></a>

###### Participants enrolled, February 2026

> “We remain committed to providing adrabetadex to the more than 60 patients currently enrolled in the EAP, and to supporting continuity of care should adrabetadex receive regulatory approval.”

Source: [Beren Therapeutics webinar community update (2026)](https://www.berentx.com/news/npc-webinar-highlights-path-forward-february-2026/)

<a id="topic-3.1.5.7.1-3"></a>

###### Participants in the survival analysis by baseline disease burden

> “Summaries were carried out for adrabetadex-treated participants with I-NPC (neurological onset <6 years) in clinical studies or the Expanded Access Program (N=80; Supplementary Table 1) and for the untreated cohort (N=44; Supplementary Table 2).”
> “Seventy-six treated participants were included in the analysis stratified by minimal (n=29, 38.2%), mild (n=20, 26.3%), moderate (n=16, 21.1%), and severe (n=11, 14.5%) baseline R4DNPCCSS scores.”
> “A total of 4 participants did not have a baseline R4DNPCCSS score and were excluded from the analysis.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.7.1-4"></a>

###### Participants in the long-term 24(S)-hydroxycholesterol study

> “Ten individuals with NPC1 participated in this study.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Baseline definitions and survival comparisons in the disease burden analysis

> “Baseline was defined as the last available observation before the first adrabetadex dose date for the pooled adrabetadex-treated participants and the first available observation for participants in the untreated cohort.”
> “Within each cohort, estimates of survival across quartiles at baseline were compared using a Mantel–Haenszel log-rank test for trend.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.7.2-2"></a>

###### Combination therapy analysis groups and observation time

| Group (participants) | Definition |
| --- | --- |
| Adrabetadex first (28) | “Participants who started adrabetadex prior to adding levacetylleucine and/or arimoclomol” |
| Any combination exposure (33) | “Participants who had exposure to levacetylleucine and/or arimoclomol at any point” |
| No combination after adrabetadex (53) | “Participants with no record of starting arimoclomol and/or levacetylleucine after starting adrabetadex” |

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

> “Time since first treatment dose is time from the first dose of adrabetadex administration to date of discontinuation from EAP or EAP cutoff date, whichever occurred earlier.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.7.2-3"></a>

###### Statistical tests in the long-term 24(S)-hydroxycholesterol study

> “A paired t-test was used to evaluate the pre/post dosing 24(S) response and Mann-Whitney test was used to compare the nonresponding and responding groups.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Duration of treatment and follow-up in the 2026 analyses

> “Participants received adrabetadex treatment for up to 11.325 years.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

> “Duration of treatment ranged from approximately 5.3 to 8.7 years and 5.3 to 11.1 years for the prompt and delayed treatment groups, respectively.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.1-2"></a>

###### Time on treatment in the long-term 24(S)-hydroxycholesterol cohort

> “Average time since initiation of intrathecal adrabetadex was 7.2 ± 1.5 years with a range of 4.3 to 8.9 years.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.8.1-3"></a>

###### Time since first dose and discontinuations in the expanded access program

| Measure | All EAP (n=86) |
| --- | --- |
| Time since first treatment dose, median [IQR], months | “52.8 [15.4, 74.2]” |
| TEAE leading to discontinuation, n (%) | “3 (3.5)” |
| TEAE leading to death, n (%) | “6 (7.0)” |

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Baseline characteristics of all expanded access participants

| Characteristic | All EAP (N=86) |
| --- | --- |
| Neurological onset <2 years, n (%) | “26 (30.2)” |
| Neurological onset 2 to 6 years, n (%) | “23 (26.7)” |
| Neurological onset ≥6 years, n (%) | “29 (33.7)” |
| Age at onset missing, n (%) | “8 (9.3)” |
| Age at neurological symptom onset, median (Q1, Q3), years (n=78) | “3.5 (1.5, 7.0)” |
| Age at adrabetadex treatment start, median (Q1, Q3), years (n=78) | “8.0 (3.0, 20.0)” |
| Male, n (%) | “51 (59.3)” |
| Female, n (%) | “34 (39.5)” |
| White, n (%) | “76 (88.4)” |
| Miglustat use at baseline, yes, n (%) | “33 (38.4)” |
| Miglustat use at baseline, no, n (%) | “46 (53.5)” |

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.8.2-2"></a>

###### Baseline characteristics of treated participants with infantile onset in the disease burden analysis

| Characteristic | Overall (N=76) |
| --- | --- |
| Neurological onset <2 years, n (%) | “33 (43.4)” |
| Neurological onset 2 to <6 years, n (%) | “43 (56.6)” |
| Age at neurological symptom onset, mean (SD), years | “2.5 (1.56)” |
| Age at adrabetadex treatment start, mean (SD), years | “7.7 (5.56)” |
| Age at adrabetadex treatment start, median (Q1, Q3), years | “6.2 (3.2, 10.8)” |
| Male, n (%) | “41 (53.9)” |
| White, n (%) | “66 (86.8)” |
| Baseline R4DNPCCSS, mean (SD) | “7.2 (5.06)” |
| Baseline R4DNPCCSS, median (Q1, Q3) | “7.0 (3.0, 10.0)” |

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.2-3"></a>

###### Baseline characteristics by time from onset to treatment

| Characteristic | Treatment initiation <1 year from onset (n=9) | Treatment initiation ≥1 year from onset (n=16) |
| --- | --- | --- |
| Age at neurological symptom onset, mean (SD), years | “2.11 (1.563)” | “2.65 (1.494)” |
| Age at adrabetadex treatment start, mean (SD), years | “2.70 (1.614)” | “7.15 (3.838)” |
| Duration from onset to treatment, mean (SD), years | “0.59 (0.324)” | “4.50 (3.308)” |
| Miglustat use at baseline, yes, n (%) | “1 (11.1)” | “9 (56.3)” |
| Baseline R4DNPCCSS, median (Q1, Q3) | “1.50 (0.50, 2.50)” | “5.00 (2.00, 10.00)” |
| Duration of treatment exposure, mean (SD), weeks | “348.37 (54.297)” | “397.23 (93.427)” |

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.2-4"></a>

###### Characteristics of the long-term 24(S)-hydroxycholesterol cohort

> “This cohort included 7 males and 3 females.”
> “Mean and median age were 20.1 ± 7.8 and 24.1(range 8.7–29.0) years, respectively.”
> “Mean and median ANO were 7.3 ± 4.1 and 6.8 (range 0–13) years.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.8.2-5"></a>

###### Characteristics of the first three expanded access patients at entry

| Subject | Age and sex | NSS | Age at onset/diagnosis | Clinical pattern |
| --- | --- | --- | --- | --- |
| 01-001 | “14 F” | “31” | “6/12” | “Cortical cognitive>motor” |
| 01-002 | “15 M” | “2” | “13/13” | “Cortical cognitive>motor” |
| 01-003 | “17 F” | “10” | “10/16” | “Cerebellar motor>cognitive” |

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

> “All 3 subjects went on Miglustat at same age as diagnosis.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Company-presented survival by baseline disease burden, pooled clinical study and expanded access participants

> “Among the adrabetadex-treated participants with minimal disease burden at baseline, no deaths were recorded.”
> “Survival probability was markedly improved across the lower quartiles in both the adrabetadex-treated participants and the untreated cohort with adrabetadex-treated participants surviving longer in each quartile.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

| Median OS (95% CI), months | Minimal quartile | Mild quartile | Moderate quartile | Severe quartile |
| --- | --- | --- | --- | --- |
| Adrabetadex-treated participants | “NE (NE, NE)” | “136 (88, NE)” | “75 (60, NE)” | “55 (12, NE)” |
| Untreated cohort | “99 (39, 192)” | “111 (62, NE)” | “62 (28, NE)” | “29 (11, NE)” |

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.3-2"></a>

###### Company summary of the CNS 2026 survival and progression analyses

> “Among 76 individuals treated with adrabetadex for up to 11 years, those with the lowest baseline disease severity (as assessed by NPC Clinical Severity Scale, NPCCSS) demonstrated the longest survival observed (n=29; 100% survival at 5 years), supporting the importance of initiating adrabetadex treatment before advanced disease progression.”
> “Among 25 patients who received adrabetadex for at least five years, both prompt and delayed treatment initiation were associated with slower disease progression relative to published natural history data.”
> “Participants who initiated adrabetadex within one year of neurological symptom onset demonstrated less progression from baseline in NPCCSS scores compared with later treatment initiation, suggesting that earlier initiation of treatment with adrabetadex may result in greater long-term clinical benefit in I-NPC.”

Source: [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/)

<a id="topic-3.1.5.8.3-3"></a>

###### Time from onset to treatment in the prompt and delayed treatment groups

> “Participants with a delayed treatment initiation started receiving adrabetadex an average of 4.5 years following neurological onset; those with prompt treatment initiation started adrabetadex an average of 0.59 year after neurological onset.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.3-4"></a>

###### Sibling case report: early and delayed treatment initiation

> “Earlier initiation of adrabetadex for Sibling B (approximately 10 months from neurological symptom onset) led to maintenance of minimal disease activity after 10 years compared to an estimated age of death of 5.6 years without treatment.”

Source: [Julich et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Julich_2026_CNS-Poster_Sibling-Case-Study_09Oct2026_Final-1.pdf)

> “Despite this delayed treatment initiation, she still experienced stabilization or improvement of her symptoms and she maintains moderate disease symptoms after approximately 10 years on adrabetadex.”

Source: [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/)

<a id="topic-3.1.5.8.3-5"></a>

###### Neurological outcomes in the first three expanded access patients over 2.5 to 3 years

> “No worsening in any domain except eye movements (vertical pursuit gain) was seen for any of the three patients, and in the other domains, improved scores on measures were seen over time for one or more patients.”
> “The NSS showed stable to slightly improved ratings.”
> “All three patients have shown substantial improvement in oral and pharyngeal phases of swallowing function as rated by the MBSImp (Table 4; Figure 6) and PAS.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.8.3-6"></a>

###### CSF 24(S)-hydroxycholesterol response after more than 4 years of treatment

> “Mean pre-drug administration CSF 24(S)OHC level was 0.27 ± 0.20 ng/ml.”
> “Mean CSF 24OHC level 48 hours after IT adrabetadex administration increased to 0.43 ± 0.22 ng/ml.”
> “This 1.6-fold average increase was significant (p=0.0289, paired t-test).”
> “24(S)OHC levels increased in 7 of the 10 individuals and the mean increase was 0.28 ± 0.34 ng/ml.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.8.3-7"></a>

###### CSF neurofilament light chain in a cohort including expanded access participants

> “The population was derived from an observational/natural history study at the NIH Clinical Center in Bethesda, Maryland (NCT00001367), from a phase I/II intrathecal trial of adrabetadex (NCT01747135), from a phase II/III intrathecal trial of adrabetadex (NCT02534844) and from individuals receiving intrathecal adrabetadex through an expanded access program (IND 119856).”
> “By the last visit, 49 (42.2%) were on HPβCD.”
> “Over time, we did not observe a protective effect of HPβCD on NfL levels (OR=1.25, 95% CI 0.99–1.58) (Supplementary Figure 2A).”
> “In fact, when adjusting the longitudinal data for the protective effect of miglustat, HPβCD was associated with increased NfL levels (OR=1.35, 95% CI 1.09–1.67).”

Source: [Agrawal et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9992339/)

<a id="topic-3.1.5.8.3-8"></a>

###### CSF total tau in a cohort including expanded access participants

> “The data set consisted of 262 measurements from 101 individuals with NPC1.”
> “Intrathecal 2HPβCD therapy was associated with a reduction in CSF total Tau levels of 19% (FDR‐adjusted p = 0.008).”

Source: [Cawley et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11893204/)

<a id="topic-3.1.5.8.3-9"></a>

###### CSF neuron-specific enolase in expanded access participants

> “Paired CSF and serum samples were obtained from a subset of ten participants receiving IT HPβCD every 2–4 weeks under the EAP.”
> “Participants on IT HPβCD experienced an average decrease of 3.7 ± 2.9 ng/mL in CSF NSE levels per year, while those not on IT HPβCD showed an average annual increase of 2.6 ± 2.5 ng/mL.”
> “This difference was statistically significant (p = .0317), suggesting that IT HPβCD treatment may reduce CSF NSE levels over time (figure 4b).”

Source: [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### School and work functioning in the first three expanded access patients

> “001-02 has had stable school performance and graduated high school with a regular curriculum and some accommodations.”
> “001-03 has had stable performance in a community college and subsequent job training program and does well with office work.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Treatment-emergent adverse events in the expanded access program by combination therapy group

| Measure | Adrabetadex first, adrabetadex-only period (n=28) | Any combination exposure, combination period (n=33) | No combination after adrabetadex (n=53) | All EAP (n=86) |
| --- | --- | --- | --- | --- |
| With ≥1 TEAE (any grade), n (%) | “28 (100)” | “23 (69.7)” | “48 (90.6)” | “81 (94.2)” |
| Leading to death, n (%) | “0” | “1 (3.0)” | “5 (9.4)” | “6 (7.0)” |
| Serious AEs, n (%) | “13 (46.4)” | “8 (24.2)” | “24 (45.3)” | “41 (47.7)” |
| Grade ≥3, n (%) | “9 (32.1)” | “6 (18.2)” | “21 (39.6)” | “33 (38.4)” |
| TEAEs of interest, n (%) | “22 (78.6)” | “9 (27.3)” | “35 (66.0)” | “62 (72.1)” |
| Ataxia, n (%) | “10 (35.7)” | “5 (15.2)” | “23 (43.4)” | “37 (43.0)” |
| Fatigue, n (%) | “17 (60.7)” | “7 (21.2)” | “25 (47.2)” | “47 (54.7)” |
| Hearing impairment, n (%) | “10 (35.7)” | “2 (6.1)” | “15 (28.3)” | “26 (30.2)” |

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

> “TEAEs of interest and grade ≥3 TEAEs were similar across the groups and the overall EAP population, except for the group who were exposed to combination therapy at any point (lowest duration of adrabetadex exposure).”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.8.5-2"></a>

###### Hearing loss, post-dose ataxia and tiredness, and lumbar puncture events in the first three expanded access patients

> “Aside from hearing changes and post-dose tiredness/ataxia known to be associated with higher doses of HPβCD, adverse events have been predominantly unrelated to the lumbar punctures (LPs) or HPβCD (Table 3).”
> “Post-LP headaches and nausea in 001-01 and 001-02 for several initial doses essentially resolved after switching to the Whitacre needle for LPs.”
> “There was persistent ataxia and tiredness at 1200 mg (Table 3) and milder post-dose ataxia and tiredness at 900 mg, lasting 3–7 days.”
> “She continues on a dose of 300 mg (Table 3) due to an incremental hearing loss and tinnitus with each of three 400 mg doses.”
> “001-03 has an unusual sensitivity to hearing loss with HPβCD, as the extent of hearing loss seen in this patient at the 400 mg dose, is not known to have been observed in any other patient worldwide.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: design limitations of the expanded access program analyses

- Control and setting: the original report of three patients names as limitations “the lack of a control group” and treatment through an expanded access protocol with likely more confounding changes from optimizing support and other treatments than in a clinical trial. Enrollment required that participants be ineligible for all currently enrolling clinical trials.
- Population counts: the prescribing information describes 85 participants (71 treatment-naïve and 14 previously treated) with a mean (SD) treatment duration of 44 (32) months.
- Dosing: doses started at 200 mg or 400 mg based on age, with titration up to 1200 mg in the initial protocol or 900 mg in the later revision, and dose adjustments were allowed.
- External comparison and analysis sets: the survival analysis by baseline disease burden compared 80 adrabetadex-treated participants with I-NPC (neurological onset <6 years) from clinical studies or the expanded access program with an untreated cohort of 44 from the NIH natural history study. Four treated participants without a baseline R4DNPCCSS score were excluded, leaving 76. Baseline was the last observation before the first dose for treated participants and the first available observation for the untreated cohort, and the authors state that “no matching procedure was performed between treated and untreated participants.”
- Prompt versus delayed treatment: the analysis included only participants with onset <6 years of age who had sustained treatment for at least 5 years, 9 with treatment initiation <1 year and 16 with initiation ≥1 year from onset, and miglustat use at baseline was 1 (11.1%) and 9 (56.3%), respectively. The company compared progression in these 25 participants with published natural history data.
- Combination therapy analysis: participants exposed to combination therapy had a shorter time since first treatment dose, as most started those therapies when they became commercially available at the end of 2024. Safety data were collected only while participants were in the study and receiving adrabetadex, and were not available for other NPC therapies received before enrollment.
- Concomitant miglustat: all three patients in the original report went on miglustat at the same age as diagnosis, and its authors state that an effect of miglustat or of the combination on progression cannot be ruled out. In the CSF neuron-specific enolase study, most participants receiving intrathecal HPβCD were also on miglustat, which the authors state makes it challenging to attribute the decrease to HPβCD alone.
- Sample size: the long-term 24(S)-hydroxycholesterol study included 10 individuals, and its authors state that its conclusions are limited by its small size; the CSF neuron-specific enolase study used a subset of ten expanded access participants.

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf); [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf); [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf); [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/); [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/); [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)

<a id="topic-3.1.5.9-2"></a>

###### Authors' limitations of the original expanded access report

> “Limitations of this work include the lack of a control group and treatment through an expanded access protocol in which there are likely more confounding changes due to optimizing support and other treatments than would be seen in a clinical trial.”
> “it is impossible to rule out an effect on progression of the Miglustat or a combined effect of Miglustat and HPβCD, which target lipid storage in NPC via different mechanisms.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.9-3"></a>

###### Unmatched comparison with the untreated cohort in the disease burden analysis

> “However, caution should be used when evaluating these two cohorts side-by-side, as no matching procedure was performed between treated and untreated participants.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.9-4"></a>

###### Shorter observation time in the combination therapy group

> “Those participants who were exposed to combination therapy at any point had a shorter time since first treatment dose in this analysis as most participants initiated these therapies when they became commercially available at the end of 2024.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.9-5"></a>

###### Small cohort size and concomitant miglustat in the biomarker studies

> “The conclusions of this study are limited by its small size; however, the data presented herein suggest that 24(S)OHC remains a robust proximal pharmacodynamic biomarker in individuals who have been treated for over four years with IT adrabetadex.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

> “Given that most participants receiving IT HPβCD were also on miglustat, it is challenging to attribute the decrease in CSF NSE solely to IT HPβCD.”

Source: [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)

<a id="heading-3.1.6"></a>

#### 3.1.6 NIH Phase 1-2a Trial

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Trial objectives: safety, tolerability, feasibility, pharmacokinetics, and active dose

> “The objectives of this study are to assess the safety, tolerability, feasibility, and pharmacokinetics (PK) of intrathecally (IT) administered HP-Beta-CD to NPC1 patients, to determine an active dose of HP-Beta-CD as measured by changes in plasma 24-(S) hydroxycholesterol (24(S)-HC) concentration, and to evaluate the use of biomarkers and potential clinical outcomes of NPC1.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.1-2"></a>

###### Primary objective of safety and primary pharmacodynamic objective of 24(S)-hydroxycholesterol response

> “Safety and tolerability of HPβCD was the primary objective, and 24(S)-hydroxycholesterol (24(S)-HC) response was the primary pharmacodynamic objective.”
> “Here we present the ad-hoc analysis of an 18-month non-randomized, open-label, phase 1/2a trial to determine safety and potential efficacy of escalating doses of lumbar intrathecal HPβCD in NPC1 participants.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.1-3"></a>

###### Objective of the 36-month neuropsychological follow-up analysis

> “The objective of this current analysis was to evaluate the change in neurodevelopmental outcomes at up to 36 months post-baseline in this Phase 1/2a trial of escalating doses of lumbar intrathecal HPβCD in NPC1.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Registry dates, enrollment, and single study location

| Field | Quoted record |
| --- | --- |
| Study start | “2013-01” |
| Primary completion (actual) | “2017-03” |
| Study completion (actual) | “2017-03” |
| Location | “National Institutes of Health Clinical Center, 9000 Rockville Pike” |
| City and state | “Bethesda, Maryland, United States, 20892” |

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.2-2"></a>

###### IND submission in December 2012 and trial start in February 2013

> “The IND was submitted in December 2012, and the Phase I Clinical Trial began in February 2013.”

Source: [Ottinger et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4048128/)

<a id="topic-3.1.6.2-3"></a>

###### Enrollment periods at the NIH Clinical Center and Rush University Medical Center

> “NIH participants were enrolled between September 2013 and January 2015. RUMC participants were enrolled between December 2013 and June 2014.”
> “Both the phase 1/2a trial of HPβCD (13-CH-0001) and the NPC1 NHx trial (06-CH-0186) were approved by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional Review Board.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.2-4"></a>

###### Assessments at the NIH Clinical Center in Bethesda

> “During each visit to the NIH Clinical Center in Bethesda, MD, USA, assessments of adverse events and clinical efficacy were performed.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Label description of Trial 2: 78-week, non-randomized, open-label, single-center dose escalation trial

> “Trial 2 (NCT01747135) was a 78-week, non-randomized, open-label, single-center cohort, dose escalation trial that enrolled a total of 14 patients between 4 and 23 years of age”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.6.3-2"></a>

###### Registry design: phase 1, non-randomized, open-label, single-center study with 3-patient dose cohorts

> “In this Phase 1, non-randomized, open-label, single-center, study, we propose to administer HP-Beta-CD intrathecally via lumbar injection to drug naive cohorts of 3 patients at doses of 200 mg escalated to 300, 400 mg and 900 mg.”
> “All patients in the cohort will receive HP-Beta-CD (n = 3) once monthly for at least two doses, and the decision to dose-escalate will be based on safety and on biochemical data.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.3-3"></a>

###### Open-label dose escalation with a natural history comparison cohort and a parallel every-two-week cohort at RUMC

> “An open-label, dose-escalation study was conducted to evaluate safety, pharmacodynamics, and efficacy of monthly intrathecal doses of 50–1200 mg of a well-characterized HPβCD mixture with a specific compositional fingerprint and limits for impurities (appendix p 3, VTS-270, Vtesse Inc., Gaithersburg MD).”
> “To explore the potential effect of every two week dosing, three additional participants were enrolled in a parallel study at Rush University Medical Center (RUMC, appendix p 2).”
> “Clinical efficacy was ascertained by comparing NSS progression in the 14 NIH HPβCD-treated participants to that observed in a historical cohort of 21 participants of similar age range (table, appendix figure 3, p 12) followed in a NHx study.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.3-4"></a>

###### Choice of the lumbar intrathecal route

> “We elected to use lumbar intrathecal administration since HPβCD does not efficiently cross the blood-brain-barrier”
> “In addition, intrathecal administration avoids potential pulmonary toxicity associated with high-dose systemic delivery”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.3-5"></a>

###### Original plan for intracerebroventricular delivery and adaptive dose escalation design

> “Pre-clinical studies were therefore directed towards supporting ICV administration of HP-β-CD in the Phase I trial using an Ommaya reservoir for delivery, Table (1).”
> “The Phase I trial is an adaptive, dose escalation study designed to systematically determine a safe and biochemically effective dose of HP-β-CD.”

Source: [Ottinger et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4048128/)

<a id="topic-3.1.6.3-6"></a>

###### Study oversight and investigator IND transferred to Vtesse

> “Study monitoring was provided by a study safety committee and an independent Data Safety Monitoring Board. Independent auditing was provided by Amarex Clinical Research (Gaithersburg, MD). An investigator IND supported the study (IND 113273). This IND was subsequently transferred to Vtesse, Inc. (Gaithersburg, MD) to support further drug development.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.3-7"></a>

###### Funding, study drug supply, and role of the funders

> “The funders had no role in study design, data collection, data analysis or decision to submit for publication. Janssen Research & Development, a Johnson and Johnson company provided the study drug and both Janssen Research & Development and Johnson and Johnson provided probono preclinical development support. Vtesse Inc. supported statistical analysis by Statistics Collaborative.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.3-8"></a>

###### NICHD-led design, data collection, and analysis

> “NICHD researchers led the design, data collection and analysis of the phase 1/2a clinical trial.”
> “The drug, 2-hydroxypropyl-beta-cyclodextrin (VTS-270), is being tested under a cooperative research and development agreement, or CRADA, between NIH and Sucampo Pharmaceuticals, Inc.”

Source: [NICHD phase 1-2a trial news release (2017)](https://www.nichd.nih.gov/newsroom/releases/nieman_pick_080917)

<a id="topic-3.1.6.3-9"></a>

###### Use of the trial data for Breakthrough Therapy designation and the phase 2b/3 trial

> “Data from this trial have been accepted by the FDA to support a Breakthrough Drug designation for VTS-270, and have supported the development and implementation of a randomized, sham-controlled, pivotal phase 2b/3 trial approved by both the FDA and EMA.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Inclusion criteria: age, NPC1 diagnosis, neurological manifestation, and stable miglustat dose

> “Aged greater than or equal to 2 and less than or equal to 25 years old at time of enrollment, either gender and any ethnicity.”
> “Patients with at least one neurological manifestation of NPC1. For example, but not limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia.”
> “Ability to travel to the National Institutes of Health Clinical Center (NIH CC) repeatedly for evaluation and follow-up.”
> “If taking miglustat, the patient must have been taking a constant dose of the medication for no less than 3 months prior to baseline evaluation and must be willing to maintain that dose level for the duration of the trial.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.4-2"></a>

###### Exclusion criteria: severe or asymptomatic disease, prior cyclodextrin, and conditions affecting lumbar puncture or audiology

> “Severe manifestations of NPC1 that would interfere with the patient's ability to comply with the requirements of this protocol.”
> “Neurologically asymptomatic patients.”
> “Patients who have received any form of cyclodextrin in an attempt to treat NPC1. Treatment with another drug preparation for another medical indication that contains cyclodextrin as an excipient, will not exclude a patient.”
> “Spinal deformity that would impact the ability to perform a lumbar puncture”
> “Contraindication for anesthesia.”
> “Patients unable to complete a behavioral audiologic evaluation including pure-tone threshold assessment (500 Hz to 8000 Hz) to monitor for ototoxicity and for whom otoacoustic emissions (OAEs) cannot be reliably obtained at baseline.”
> “Patients with ongoing seizures, that are not stable in frequency, type or duration over a 2 month period prior to enrollment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2 month period prior to enrollment, or requiring 3 or more antiepileptic medications to control seizures.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.4-3"></a>

###### Eligible ages and onset category of enrolled participants

> “Eligible participants were aged 2 – 25 years and neurological manifestations, although participants were excluded if these were severe. All participants had neurological symptoms by 13 years of age thus would be categorized as childhood/adolescent onset.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.4-4"></a>

###### Diagnosis by clinical, cellular, and molecular criteria and selection of the comparison cohort

> “The diagnosis of NPC1 disease was established by a combination of clinical, cellular and molecular criteria (appendix pp 2–3).”
> “The NIH NHx population was used as the comparison group, and participants were selected based on two criteria: the presence of two or more assessments within a 25 month time period and an age range of 4 to 24 years at the first of any two or more assessments.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Label description of Trial 2 dosing: 200 to 1,200 mg once monthly

> “LEMBAZ was administered intrathecally at a dosage that ranged from 200 to 1,200 mg once monthly (these dosage regimens are not recommended [see Dosage and Administration (2.2)]), with patients up-titrated based on tolerability and efficacy.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.6.5-2"></a>

###### Formulation, infusion volume, starting doses, and mean doses at 12 and 18 months

> “HPβCD was formulated as a 20% solution and diluted in saline to provide an infusion volume of 10 ml, which was infused over 2–3 minutes.”
> “HPβCD was administered monthly by lumbar intrathecal infusion for the NIH participants. Dosing for CDA101–112 was initiated at 50, 200, 300, or 400 mg HPβCD in groups of 3 participants, and the dose (appendix figure 2, p 11) was advanced based on tolerance and safety data from higher dose cohorts. Mean doses at 12 and 18 months were 289 ± 68 mg and 423 ± 142 for CDA101–112, respectively.”
> “CDA113 and CDA114 were dosed at 900 mg for 12 months. HPβCD was administered every two weeks to the RUMC cohort and their mean dose at 18 months ranged from 297 to 481 mg (figure 1B).”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.5-3"></a>

###### Sequential starting-dose assignment and escalation to 600 or 1200 mg

> “HPβCD (VTS-270) was formulated and provided by Johnson & Johnson (Janssen Research and Development).”
> “Patients were sequentially assigned to starting doses of 50 mg (CDA101–103), 200 mg (CDA104–106), 300 mg (CDA107–109), and 400 mg (CDA110–112). Two participants (CDA113–114) were initially dosed at 900 mg. After initial dosing, participants were dose-escalated (to 600 or 1200 mg) as tolerated.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.5-4"></a>

###### Dose increase for all participants after high doses were tolerated

> “Initially, participants were divided into groups receiving different doses of the drug, but after observing that the drug was safe and well-tolerated by those receiving the highest doses, the researchers increased dosing for all participants.”

Source: [NICHD phase 1-2a trial news release (2017)](https://www.nichd.nih.gov/newsroom/releases/nieman_pick_080917)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Plasma 24(S)-Hydroxycholesterol Area Under the Curve as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Registered primary and secondary outcome measures

| Outcome role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “24-hydroxycholesterol Area under the curve” | “Days” |
| Secondary | “Hearing loss.” | “Year” |

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.6.1-2"></a>

###### Plasma 24(S)-hydroxycholesterol as a neuron-derived pharmacodynamic marker of cholesterol homeostasis

> “In preclinical studies, treatment with HPβCD was shown to redistribute lysosomal cholesterol, resulting in modulation of a range of central nervous system (CNS) sterol homeostatic responses, including synthesis of 24(S)-HC.”
> “measurement of 24(S)-HC in response to HPβCD provides a pharmacodynamic marker of improved neuronal cholesterol homeostasis.”
> “Plasma 24(S)-HC concentrations were determined at pre-dose, 8, 24, 30, 48, and 72 hours post-dose after either saline or HPβCD infusion and the area under the curve was determined (AUC8–72).”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.6.1-3"></a>

###### Biochemical efficacy defined as change from baseline in plasma 24(S)-hydroxycholesterol

> “Biochemical efficacy will be measured by change from baseline in plasma 24(S)-HC.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.6.1-4"></a>

###### Secondary efficacy endpoint: NPC Neurological Severity Score

> “Clinical efficacy was evaluated using the NSS.”
> “NPC1 disease progression has been characterized using the NPC Neurological Severity Score (NSS). The NSS is a Likert-like scale that assesses severity of clinically relevant signs and symptoms in nine major and eight minor domains (appendix, p 10).”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.6.1-5"></a>

###### Development of the severity scale and linear progression independent of age of onset

> “The absence of a universally accepted clinical outcome measure is an impediment to the design of a therapeutic trial for NPC. Thus, we developed a clinical severity scale to characterize and quantify disease progression.”
> “Longitudinal chart review of historical data demonstrated that although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients.”

Source: [Yanjanin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2798912/)

<a id="topic-3.1.6.6.1-6"></a>

###### Exploratory CSF biomarkers of neuronal damage: FABP3 and calbindin D

> “CSF levels of fatty acid binding protein 3 (FABP3) and calbindin D were assayed by Myriad Rules Based Medicine (Austin, TX).”
> “Elevated FABP3 has been reported as a biomarker for neurodegenerative disorders”
> “Neither calbindin D nor FABP3 have been established as clinical surrogates, but our observation that CSF levels decrease in temporal relationship with HPβCD therapy is consistent with the conclusion that intrathecal HPβCD decreases neuronal damage in NPC1 participants.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.6.1-7"></a>

###### Neuropsychological outcomes in the 36-month follow-up: IQ and adaptive behavior

> “The primary neurocognitive outcomes in this study were IQ and adaptive behavior.”
> “While conclusions regarding changes over time are limited overall, the presentation of data from various measures and types of scores suggest that the adaptive behavior age equivalent scores are the most clinically useful scores for studies of this nature.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Actual enrollment of 14 participants

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “14” |
| Phase | “Phase 1” |

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.7.1-2"></a>

###### Fourteen participants treated monthly and three treated every two weeks, with no formal sample size calculation

> “Intrathecal doses ranging from 50–1200 mg were evaluated in 14 neurologically affected NPC1 participants treated monthly for 12 to 18 months. Three additional participants were treated every two weeks for 18 months.”
> “No formal calculation of sample size was made for ad-hoc analysis of the NSS, and given the small sample size we are not estimating confidence intervals.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.7.1-3"></a>

###### No a priori power calculation for the neuropsychological analyses

> “No a priori power calculation was performed for these analyses.”
> “The sample size in this study is just commensurate with the minimum suggested for valid interpretation of fixed effects and variance (n ≈ 15), but is below that suggested for the standard errors of the fixed effect (n ≈ 30)”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Post hoc mixed model repeated measures analysis of annualized NSS slope versus the natural history cohort

> “A post hoc mixed model repeated measures approach was used to assess the efficacy of HPβCD in this population.”
> “The primary analysis estimates the slope as change in score per year from a mixed model repeated measures (MMRM) model with time, group (HPβCD-treated participants or NIH NHx study participants), and a group by time interaction term.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.7.2-2"></a>

###### Responder analysis based on change from baseline in each NSS domain

> “For the responder analysis, a change from baseline was used to assess the efficacy of HPβCD in individual participants. The NIH NHx population was used as the comparison group; the subject selection criteria were as described for the MMRM approach.”
> “Fisher’s exact test was used for the responder analysis. Unless otherwise specified, data are expressed as mean ± SEM and a nominal p-value of 0.05 was considered significant.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.7.2-3"></a>

###### Audiometric analysis set

> “Behavioral thresholds for pure-tone stimulation could be established for 12/14 participants.”
> “Behavioral audiograms could not be obtained on participants CDA112 and CDA113 due to inability of these participants to perform this testing.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.7.2-4"></a>

###### Neuropsychological analysis set: participants with any available data

> “Participants with any available data were included in analysis; list-wise deletion was not used. However, where missing data resulted in a sample size <10 at more than one major assessment point, parametric analysis was not performed.”
> “No comparison group was available, so the goal of this set of analyses was to describe the course of the neuropsychological outcomes during the trial.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Timing of the final NSS evaluation by participant

> “NSS evaluations were at 18 months for participants CDA101 and CDA103–111. The 18-month evaluation for CDA112 was obtained at 19 months. NSS data corresponding to CDA102, CDA113 and CDA114 were obtained at 12 months and data corresponding to the three RUMC participants were obtained at 18 months.”
> “Enrollment of participants at the NIH Clinical Center (n=14) between September 2013 and January 2015 and participants at RUMC (n=3) between December 2013 and June 2014.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.1-2"></a>

###### Follow-up to 36 months for neuropsychological outcomes

> “This analysis includes outcomes collected out to 36 months post-baseline.”
> “Fewer than 10 WRAML observations were available at most timepoints (including baseline), so these data were not subjected to parametric analysis.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Baseline characteristics of the NIH treated cohort and the natural history comparison cohort

| Characteristic | Natural History Cohort (n=21) | NIH HPβCD Treated Cohort (n=14) |
| --- | --- | --- |
| Total NSS at baseline, mean | “14.5 ± 9.7” | “19.3 ± 7.5” |
| Total NSS at baseline, median (range) | “14 (1–35)” | “19(5–32)” |
| Total NSS-hearing at baseline, mean | “13.2 ± 9.4” | “17.0 ± 7.4” |
| Age of first neurological symptom, years, mean | “5.4 ± 4.2” | “5.9 ± 3.5” |
| Age of diagnosis, years, mean | “7.1 ± 6.5” | “9.1 ± 5.6” |
| Age of diagnosis, years, median (range) | “7.0 (0.3–21.0)” | “9.0 (2.0–20.0)” |
| Miglustat use, yes, number (%) | “16 (76)” | “12 (86)” |

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.2-2"></a>

###### Comparability of the treated and natural history cohorts at baseline

> “On average NHx patients were younger and had lower NSS at baseline, but these differences were not significant.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.2-3"></a>

###### Baseline hearing loss in all participants

> “Hearing loss (>15 dB HL for at least one frequency) was present at baseline in all participants. Based on these audiograms, seven participants were candidates for hearing aids.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.2-4"></a>

###### Participant information for the 14 NIH participants in the neuropsychological follow-up

| Characteristic | Mean ± standard deviation | Range |
| --- | --- | --- |
| Age at diagnosis (years) | “9.07 ± 5.65” | “2 − 20” |
| Age at baseline (years) | “15.07 ± 5.53” | “4 − 23” |
| Niemann-Pick Type C1 Total Severity Score at Baseline | “19.29 ± 7.46” | “5 − 32” |

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

| Characteristic | n (%) |
| --- | --- |
| Female | “7 (50%)” |
| White | “14 (100%)” |
| Non-Latino/Non-Hispanic | “13 (93%)” |
| Hearing loss at baseline | “11 (79%)” |
| Seizures | “5 (36%)” |
| Miglustat | “11 (79%)” |

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Plasma 24(S)-hydroxycholesterol response after intrathecal dosing

> “The majority (121/155) of post-drug plasma 24(S)-HC AUC8–72 values were greater than post-saline values; however, plasma responses were more variable and less robust compared to what was observed in preclinical testing (appendix figure 4A, pp 13–14).”
> “Despite the variability, the data suggested a trend for increased 24(S)-HC response at higher doses and significant increases in individual subject responses were observed at 900 and 1200 mg (figures 2A and2B).”
> “Each paired set of pre/post values represents an individual dose: for 900 mg, n=18 doses among 8 subjects; for 1200 mg, n=13 doses among 7 subjects.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-2"></a>

###### CSF 24(S)-hydroxycholesterol response in three participants

> “The CSF 24(S)-HC concentrations in three participants treated with 600–900 mg of HPβCD were increased over two-fold”
> “In contrast, the increase in CSF 24(S)-HC concentration after HPβCD administration was unambiguous.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-3"></a>

###### CSF FABP3 and calbindin D decreased from baseline

> “Significant decreases were observed when comparing baseline and final CSF FABP3 (D) and calbindin D (E) levels.”
> “We also observed that CSF calbindin D and FABP3 levels, biomarkers of neuronal damage, decreased significantly in the majority of HPβCD-treated participants.”
> “These data provide evidence that treatment with HPβCD shifts, towards normal, CSF biomarkers of CNS pathology.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-4"></a>

###### Annualized total NSS progression versus the natural history comparison cohort, as printed in the author manuscript

> “The total NSS for the 14 participants treated monthly increased at a slower rate of 122 ± 0 34 points/year compared to 2 92 ± 0 27 points/year (p=0 0002) for the comparison cohort (figure 4A).”
> “These data demonstrate a significant reduction in disease progression in the HPβCD-treated cohort.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-5"></a>

###### NSS domains: decreased progression in ambulation, cognition, and speech and increase in hearing

> “Annualized rate of disease progression is decreased for ambulation, cognition, and speech in the intrathecal HPβCD-treated participants in comparison to the NHx group. Only the hearing subdomain demonstrated a notable annualized increase in progression in the HPβCD-treated group. This is consistent with the known ototoxicity of HPβCD.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-6"></a>

###### Responder analysis: 7 of 14 treated participants versus 21 of 21 comparison participants progressed

> “Individuals with a decreased or stable NSS minus hearing were considered to be responders.”
> “In the NHx cohort 21/21 (100%) demonstrated disease progression (figure 4C); whereas, 7/14 (50%) of the participants in the HPβCD-treated group demonstrated disease progression (figure 4D). The RUMC participants treated every 2 weeks were all responders.”
> “Furthermore, a responder analysis showed decreased or stabilized NSS in 10/17 HPβCD-treated participants while 21/21 comparison subjects demonstrated disease progression.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-7"></a>

###### Individual pre-treatment and on-treatment NSS in eight participants

> “Individual pre/post NSS for eight participants where pretrial data were available are provided in appendix figure 6 (pp 17–18). Stabilization or slowing of NPC1 disease progression can be appreciated in six of eight participants.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-8"></a>

###### Sensitivity analyses: miglustat-treated participants and inclusion of the every-two-week RUMC cohort

> “Sensitivity analyses showed similar results when the analysis was restricted to participants treated with miglustat and were suggestive of increased efficacy with every two week dosing.”
> “The limited data available from the RUMC participants suggests that every two week dosing may be more effective than monthly dosing.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-9"></a>

###### Intelligence quotient over 36 months

> “The average annualized change in FSIQ was negative: B = −1.28, SE = 0.70, t(34.2) = −1.83, p =0 .076. The slopes in each of the IQ subdomains were weaker: NVIQ, B = −0.65, SE = 0.82, t(35.3) = −0.79, p = 0.43; VIQ, B = −0.80, SE = 1.02, t(34.3) = −0.79, p = 0.44.”
> “Up to 36-months post-baseline, there were no significant declines in the areas of cognition and adaptive behavior.”
> “In conjunction with previous findings, these results provide support for the slowing of disease progress up to 36 months post-initiation of intrathecal VTS-270.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.8.3-10"></a>

###### Memory scores over 36 months

> “The median change in scaled score was slightly negative at most time points for Memory, Recall, and Recognition.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.8.3-11"></a>

###### Plasma and CSF N-palmitoyl-O-phosphocholineserine in trial participants

> “The plasma samples collected from NPC1 study participants in Phase 1/2a trial of IT HPβCD at pre-dosed time point in each visit were used to evaluate the long-term effect of IT HPβCD on PPCS.”
> “PPCS was decreased, increased, and unchanged in 44% (Figure 2B), 17% (Figure 2C), 33% of subjects (Figure 2D), respectively.”
> “In the IT HPβCD trial, the pre-treatment CSF samples supplied with 2% CHAPS that prevented absorption loss of PPCS were collected from only 2 study participants. CSF PPCS did not change after HPβCD treatment in these 2 individuals (Figure 3E).”

Source: [Sidhu et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145728/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

###### Caregiver-interview measure of adaptive behavior: Vineland Adaptive Behavior Scales

> “The Vineland is a semi-structured caregiver interview that assesses adaptive functioning in Communication, Daily Living Skills, Socialization, and Motor Skills (standard scores available only for children under the age of 7 years).”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.8.4-2"></a>

###### Vineland standard scores and age equivalents over 36 months

> “On average, the Vineland-II ABC standard score decreased by 1.76 points per year [SE = 0.67, t(59.1) = −2.62, p = 0.011].”
> “However, examination of the average age equivalent scores (in months) for these domains (shown in Figure 2) indicated that the small decreases in standard scores were not due to worsening, but rather to slower-than-typical (or no) acquisition of skills.”
> “Annualized slopes for each of the domain age equivalents were positive, although the 95% CI included zero: Communication [B = 0.71, SE = 3.12, t(60.7) = 0.23, p = 0.82], Socialization [B = 2.99, SE = 2.92, t(60.4) = 1.03, p = 0.30], Daily Living Skills [B = 2.76, SE = 2.76, t(60.3) = 1.18, p = 0.24], and Motor Skills [B = 1.42, SE = 0.94, t(50.5) = 1.51, p = 0.14].”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.8.4-3"></a>

###### Effect of treatment-related hearing loss on daily communication

> “When managed with hearing aids, this did not have an appreciable impact on daily communication.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.4-4"></a>

###### Hearing aids and daily life

> “In the current study, hearing loss was compensated with hearing aids, which enabled participants to go about their daily lives.”

Source: [NICHD phase 1-2a trial news release (2017)](https://www.nichd.nih.gov/newsroom/releases/nieman_pick_080917)

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Safety assessment methods: CTCAE grading and monthly audiology

> “Severity of adverse events was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Audiological assessments were obtained monthly prior to each infusion.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-2"></a>

###### No drug-related serious adverse events; post lumbar puncture headache and ototoxicity as expected adverse events

> “No drug-related serious adverse events were observed. Mid- to high-frequency hearing loss, an expected adverse event, was documented.”
> “Notable expected adverse events included participants with post lumbar puncture headache (64%, 9/14) and ototoxicity (100%, 14/14).”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-3"></a>

###### Transient post-dose unsteadiness and fatigue at doses above 600 mg

> “Notable unexpected adverse events included post-administration unsteadiness and fatigue at doses above 600 mg. This was transient and typically occurred 24–72 hours after dosing. The degree of impairment was variable across participants, but classified as significant in 3/9, 6/12 and 9/9 participants at 600, 900 and 1200 mg, respectively. The unsteadiness and fatigue may variably attenuate with repetitive dosing at a given dose level.”
> “From a safety standpoint, doses up to 1200 mg were generally well tolerated. The transient post-dose ataxia/fatigue observed in this study may be a dose-limiting side effect, especially if the dose or frequency of dosing is increased.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-4"></a>

###### Hepatocellular carcinoma in one participant

> “One subject presented with hepatocellular carcinoma during the trial.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-5"></a>

###### Additional mid- to high-frequency hearing loss in all participants

> “After HPβCD administration, all participants demonstrated additional mid- to high-frequency hearing loss, and all participants were hearing aid candidates.”
> “Broad variation in the degree of ototoxicity in individual participants was observed.”
> “These data suggest that there is greater HPβCD ototoxicity in individuals who have not yet lost hearing due to NPC1 disease itself.”
> “At study end, all participants had functional deficits in hearing, but these deficits did not appreciably impact daily communication when managed with hearing aids.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-6"></a>

###### Grade 3 hearing loss in one RUMC participant and tinnitus

> “One subject (RUMC03) demonstrated marked sensitivity to HPβCD with CTCAE grade 3 hearing loss upon initial dosing at 400 mg; however, subsequent administration of 300 mg HPβCD every two weeks did not result in additional ototoxicity.”
> “Although not every patient could reliably self-report tinnitus, it appeared to be associated with HPβCD administration. Tinnitus was limited to the post-dose time period in two cases, but persistent in four participants.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary: design limitations of the NIH phase 1-2a trial

- Control and external comparison: the trial was a non-randomized, open-label, single-center dose escalation study. The authors state that it “relies on a historical comparison group, and is not a randomized, placebo-controlled trial.” Efficacy compared NSS progression in the 14 NIH participants with a historical cohort of 21 participants from a natural history study, selected for two or more assessments within 25 months and an age of 4 to 24 years. Natural history participants were on average younger and had lower NSS at baseline (mean total NSS 14.5 ± 9.7 versus 19.3 ± 7.5), differences the authors report as not significant.
- Analysis: the clinical efficacy data come from an ad-hoc analysis using a post hoc mixed model repeated measures approach. No formal sample size calculation was made, confidence intervals were not estimated given the small sample size, and the responder analysis used Fisher's exact test with a nominal p-value of 0.05.
- Dose escalation: the authors state that the dose escalation design limits the ability to establish dose-response correlations. The publication describes monthly doses of 50 to 1200 mg in the 14 NIH participants and every-two-week dosing in three additional participants at Rush University Medical Center; the prescribing information describes doses of 200 to 1,200 mg once monthly, regimens it does not recommend.
- Unequal follow-up and measurement: NSS data for three participants (CDA102, CDA113, and CDA114) were obtained at 12 months and for the others at 18 or 19 months. Behavioral audiograms could be obtained for 12 of 14 participants.
- Concomitant miglustat: 12 (86%) treated and 16 (76%) natural history participants used miglustat. In the 36-month neuropsychological analysis, 11 of 14 participants took miglustat at baseline and throughout, and the small number not taking it prevented assessment of its confounding effect.
- Neuropsychological follow-up: the analysis had no comparison or historical control group, was descriptive because the study was not designed to target neuropsychological efficacy, had no a priori power calculation, and had a sample below the n ≈ 30 suggested for the standard errors of the fixed effect. Fewer than 10 WRAML observations were available at most timepoints.
- Confirmation: the authors state that data from a randomized, sham-controlled phase 2b/3 study would be needed to confirm the results.

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/); [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.9-2"></a>

###### Limitations stated by the trial authors: historical comparison group, ad-hoc analysis, and dose escalation design

> “This study has several limitations. First, it relies on a historical comparison group, and is not a randomized, placebo-controlled trial. Second, the clinical efficacy data is based upon an ad-hoc analysis. Third, the dose escalation design focused on determining safety and tolerability limits our ability to establish dose-response correlations with biomarker and clinical data.”
> “Additional work is required to determine if ototoxicity can be separated from neurological efficacy; however, in the context of a lethal neurodegenerative disorder, the risk of functional hearing impairment that can be managed with hearing aids can be justified.”
> “Data from a multicenter, international, randomized, sham-controlled phase 2b/3 study will be needed to confirm the results of this study and obtain FDA and EMA approval.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.9-3"></a>

###### Limitations of the 36-month neuropsychological analysis: no control group and concomitant miglustat

> “Additionally, we were not able to include a historical control group.”
> “The descriptive nature of this report was necessary because the study was not designed to specifically target clinical efficacy with respect to neuropsychological functioning. Finally, 11 of 14 participants were taking miglustat at baseline and throughout the trial. Due to the small number of participants not taking miglustat, we were unable to ascertain its potential confounding effect.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

Additional sources: [Erickson and Fiorenza (2017)](https://pubmed.ncbi.nlm.nih.gov/28803711/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
